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ABSTRACT
Parkinson’s disease is the commonest neurodegenerative movement
disorder. Although the pathological loss of dopaminergic neurons in
the substantia nigra has long been recognised, the disease remains
incurable because the mechanisms underlying this loss are not un-
derstood. Finding genes that cause inherited forms of the disease can
help by pinpointing pathways that lead to neuronal death when faulty.
However, analysis of these genes is complicated by the inaccessibility
of diseased tissue during life.
One possible solution is to use fibroblasts from patients, which retain
pathogenic mutations and might act as a surrogate for diseased cells.
But a major advance might be provided by reprogramming fibroblasts
into induced pluripotent stem cells. These can be differentiated into
multiple cell lineages, including those specific cells affected by disease.
Here, two studies are described using fibroblasts from Parkinson’s
disease patients with LRRK2 mutations. The first suggests that 4E-
BP, a component of the mTOR pathway, is hyperphosphorylated in
patient fibroblasts. In contrast, the second study suggests that gene
transcription is not significantly altered in these cells.
To improve on this non-neuronal model, induced pluripotent stem
cells were generated using fibroblasts from a Parkinson’s disease
patient with triplication of the a-synuclein locus, alongside healthy
controls. When these cells are differentiated into dopaminergic neu-
rons, those from the patient have double dosage of a-synuclein protein,
but only when clonal variation and efficiency of neuralisation are ad-
dressed. Nevertheless, these cells precisely recapitulate the cause of
Parkinson’s disease in this kindred.
These studies demonstrate the feasibility of generating cells of in-
terest from a patient with a neurodegenerative disorder, but also
v
highlight the inherent variability in induced pluripotent stem cell sys-
tems. These data emphasise the need for robust methods of neuronal
differentiation, and the need to generate multiple induced pluripo-
tent stem cell clones from each subject when developing such disease
models.
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Part I
BACKGROUND
1
INTRODUCTION
Involuntary tremulous motion . . .
with a propensity to bend the trunk forward,
and to pass from a walking to a running pace:
the senses and intellects being uninjured.
— Parkinson (1817)
Parkinson’s disease (PD) is the most common neurodegenerative move-
ment disorder, estimated to affect one person in every 500. Prevalence
increases with age, thus PD is set to become even more common
with our ageing population. The economic burden in the UK alone
is already upwards of £6 billion per annum (Findley et al., 2003). No
curative or disease modifying treatments exist for this condition, ow-
ing to the fact that we understand relatively little about why certain
neurons progressively die off in the disease.
1.1 historical perspective
Possibly the earliest recorded descriptions of PD are housed in the
ancient library of the Hindu University of the Holy City of Benares
(Varanasi), in which can be found the Charakasamhita, a Sanskrit
treatise on Ayurvedic medicine compiled by Agnivesha (c2500 bc).
Chapter 20 of this volume (entitled Vepathy) contains descriptions of
different patterns of tremor, some of which are associated with certain
Vatas or palsies (Stern, 1989).
An Egyptian papyrus of the nineteenth dynasty (c1350–1200 bc)
describes a king with what resembles Parkinsonian dribbling:
2
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“A divine old age had slackened his mouth. He cast his
spittle upon the ground and spat it out.” (Stern, 1989).
Later, Galen (129–199), born in Pergamon, studied in Alexandria and
exposed to the Platonic, Stoic and Epicurean schools, became the most
influential physician since Hippocrates. There are many references to
tremor in his writings:
“It is the impairment of the free exercise of one’s faculties
. . . it is an unfortunate condition in which movement is
unstable and not under one’s own control . . . ” (Galen,
1539).
He also recognises gait disorders including scelotybre (troubled limbs):
“a kind of paralysis which prevents people walking straight
by mixing up the sides . . . failing to lift the foot and putting
it back instead, like those walking up a steep incline.”
(Galen, 1539).
Following these historical glimpses, in 1817 James Parkinson published
a monograph entitled An Essay on the Shaking Palsy, the first detailed
description of the disease which would later bear his name (Parkinson,
1817). He personally examined three of the cases, and observed the
other three on the streets of London, near his Hoxton home. He
described the three hallmark characteristics of the disorder which
he referred to as ’paralysis agitans’: tremor, rigidity and slowness
of movement (bradykinesia) (Jankovic, 2008). By the late 1800s, Jean-
Martin Charcot credited him with these original reports by renaming
the condition ’maladie de Parkinson’ or Parkinson’s disease.
Nearly a century after Parkinson’s published observations, Friedrich
Lewy reported the presence of abnormal intraneuronal inclusions
(subsequently called Lewy bodies, in his honour) in the brains of PD
patients at autopsy (Lewy, 1912) and a few years later, Constantin
Tretiakoff established that the substantia nigra is the main structure
affected by the disease (Tretiakoff, 1919).
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Once the anatomy of the disease had been clarified, the next step
was to confirm the pharmacology. In 1957, Arvid Carlsson reported
dopamine as a putative neurotransmitter (Carlsson et al., 1957). Shortly
thereafter, Ehringer and Hornykiewicz found that dopamine concen-
trations are markedly reduced in the striatum of PD patients (Ehringer
and Hornykiewicz, 1960). They later found that this deficiency is
specifically due to loss of midbrain dopaminergic neurons. Confirma-
tion of the critical role of dopamine was established in 1961, when
intravenous l-dopa, a metabolic precursor of dopamine, was first
shown to relieve the symptoms of PD (Birkmayer and Hornykiewicz,
1961). By the late 1960s, oral l-dopa had been established as a viable
symptomatic treatment for PD (Cotzias et al., 1969).
The next phase of PD research was triggered by the accidental
exposure of a group of Californian drug users to the toxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the early 1980s (Langston
et al., 1983). This toxin caused an acute, irreversible Parkinsonian
syndrome via inhibition of complex I of the mitochondrial electron
transport chain, which rapidly caused the death of midbrain dopamin-
ergic neurons with remarkable specificity. Reduced complex I activity
was subsequently found in sporadic PD brain at postmortem (Schapira
et al., 1989). By this point it was clear that mitochondria must surely
play a central role in maintaining the viability of midbrain dopaminer-
gic neurons.
The most recent era of PD research, which continues to this day,
began with the discovery of the first genetic cause of PD – a condition
that historically had been regarded as a sporadic disorder. In 1997,
mutations in the SNCA gene (which encodes a-synuclein) were discov-
ered in a large Greek-Italian kindred, many members of which had PD
inherited in an autosomal dominant fashion (Polymeropoulos et al.,
1997). Whilst SNCA mutations remain a particularly rare cause of PD,
more recently a much more commonly mutated gene, called LRRK2,
was codiscovered by two independent research groups as a cause of
autosomal dominant PD, and simultaneously reported (Paisan-Ruiz
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et al., 2004; Zimprich et al., 2004)). These two genes form the focus of
investigation for this thesis.
To date, over a dozen loci have been linked to familial PD, and
several further responsible genes have been cloned. A summary of
Mendelian genes linked to PD is shown in Table 1.1.
1.2 a-synuclein, lewy bodies and synucleinopathies
Depigmentation of the substantia nigra (a marker of loss of dopamin-
ergic neurons from this area) is a pathological hallmark of PD. Lewy
bodies are seen in surviving nigrostriatal neurons at autopsy and are
required to make a pathologically-defined diagnosis of this disorder
(Braak and Braak, 2000). A53T was the first point mutation described
in SNCA, in a Greek/Italian kindred (Polymeropoulos et al., 1997).
Two other missense mutations, A30P (Krüger et al., 1998) and E46K
(Zarranz et al., 2004), have since been reported in German and Spanish
kindreds respectively (see Figure 1.1 for a summary of SNCA muta-
tions). The protein encoded by SNCA, a-synuclein, was subsequently
discovered to be the predominant constituent of Lewy bodies, suggest-
ing that it plays a central role in the pathogenesis of PD (Spillantini
et al., 1997).
Triplication of the SNCA locus has also been reported in a separate
kindred with familial PD (Singleton et al., 2003); branches of this
family had been previously reported, but found via genealogical meth-
ods to be the same (Iowa, Spellman-Muenter, Waters-Miller kindred)
(Spellman, 1962; Waters and Miller, 1994; Muenter et al., 1998; Farrer
et al., 1999). Affected individuals from this kindred, with four copies
of SNCA rather than the normal two, were found to have a correspond-
ing doubling of SNCA mRNA and a-synuclein protein in post-mortem
brain tissue (Miller et al., 2004). The observation that SNCA multipli-
cation as well as point mutation can cause disease parallels a similar
mechanism in Alzheimer’s disease (AD) pathogenesis where either in-
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Figure 1.1: a-Synuclein ideogram showing the positions of the three patho-
logical mutations (A30P, E43K and A53T). Phosphosites on a-
synuclein are indicated by red circles. a-Helices are represented
by blue and b-sheets/turns indicated by areas of green. Adapted
from Hardy et al. (2009).
creased dosage or missense mutations of the APP (amyloid precursor
protein) gene causes early onset disease (Hardy, 2006).
Two large genome wide association studies have established SNCA
variation as the most important genetic risk factor for sporadic PD
(Satake et al., 2009; Simon-Sanchez et al., 2009). Considering all of the
above findings, understanding a-synuclein biology is clearly pivotal
to our understanding of PD and much of the basic research into
the disease over the last decade has centred on this protein. In the
following section I will review the phenotypic spectrum of SNCA gene
dosage alterations, and discuss how this informs our understanding
of PD pathogenesis.
1.3 snca multiplication kindreds
1.3.1 Iowa kindred
The Iowa kindred is striking because of the wide range of disease seen
in family members, probably the consequence of the large size of the
kindred, described since the early 1900s (Spellman, 1962; Waters and
Miller, 1994; Muenter et al., 1998; Farrer et al., 1999). Video documen-
tation of several members of this kindred is available in Gwinn et al.
(2011). Muenter et al. (1998) gave a detailed account of 13 affected
individuals from this family over four generations with ’hereditary
parkinsonism with dementia’. Clinical and pathological features of
most affected members were typical for PD except for earlier age of
1.3 snca multiplication kindreds 8
onset (mean age 33) and more fulminant course (mean life expectancy
8.1 years after disease onset, in contrast to 18.4 years in sporadic PD
with onset before age 50 (Hoehn and Yahr, 1967)).
Many affected individuals in the family have carried the diagno-
sis of PD, and met published clinical criteria (except for a positive
family history) (Hughes et al., 2001). Positron Emission Tomography
scanning with 6-[18F]fluorodopa has revealed severe depletion of stri-
atal dopamine in those family members with typical PD clinically
(Muenter et al., 1998), and the presence of Lewy bodies and neuronal
loss in the substantia nigra has been well described (Gwinn-Hardy
et al., 2000). However, others have more prominent and early demen-
tia, with parkinsonism, hallucinations, and fluctuations in cognition,
consistent with dementia with Lewy bodies (DLB), which has been
correlated pathologically with cortical Lewy bodies and Lewy neurites
(McKeith et al., 2003). Another individual in this family had clinical
features of parkinsonism, dementia, and dysautonomia, and dramatic
a-synuclein immunoreactive glial inclusions were seen at autopsy –
neuropathologically consistent with multiple system atrophy (MSA)
(Gwinn-Hardy et al., 2000).
PD, DLB and MSA are collectively known as synucleinopathies, be-
cause they feature intracellular a-synuclein deposition neuropatholog-
ically, and a-synuclein is believed to be integral to their pathogenesis
(Spillantini and Goedert, 2000). Therefore, the clinical phenomenol-
ogy within this one kindred demonstrates that increased dosage of
a-synuclein can generate the full spectrum of synucleinopathies.
1.3.2 Additional SNCA triplication kindreds
Farrer et al. (2004) documented a separate SNCA triplication kindred,
called the Swedish-American kindred, after screening 42 probands
with early-onset autosomal dominant PD. The proband had a similar
phenotype to some Iowa kindred affecteds, with a rapidly progres-
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sive dopa-responsive parkinsonism starting age 31 years. Postural
hypotension, visual and auditory hallucinations arose 14 years later
with worsening dementia, severe generalised rigidity and death aged
52. Elevated SNCA mRNA was found in postmortem brain tissue of
affecteds, with doubling of a-synuclein protein, corroborating equiv-
alent findings in the Iowa kindred (Miller et al., 2004). Severe neu-
ronal degeneration in the substantia nigra and locus coeruleus, with
widespread Lewy body pathology, was seen at autopsy. There was also
severe neuronal loss in the CA2/3 area of the hypothalamus – unusual
for PD or DLB but similar to that seen in six of seven autopsied cases
from the Iowa kindred (Waters and Miller, 1994; Muenter et al., 1998;
Gwinn-Hardy et al., 2000).
Ibanez et al. (2009) described a French kindred with SNCA tripli-
cation after screening 22 families with atypical autosomal dominant
parkinsonism. The three affecteds had rapidly evolving symptoms
with severe cognitive impairment and short disease duration until
death (mean 7 years).
The fourth triplication kindred reported to date is a Japanese fam-
ily comprising three individuals of consecutive generations afflicted
with early-onset parkinsonism with dementia and orthostatic hypoten-
sion (Sekine et al., 2010). Triplication was confirmed in the grandson,
with disease onset of 31. His father had disease onset aged 31 (and
died aged 40). The proband’s grandfather’s age of onset was 49; he
subsequently died aged 57.
Clinical features of members of these triplication kindreds are sum-
marised in Table 1.2 (rigidity and bradykinesia were present in all
cases).
1.3.3 SNCA duplication kindreds
SNCA duplication is now also recognised as a rare cause of familial
parkinsonism, including cases which are phenotypically similar to
1.3 snca multiplication kindreds 10
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1.3 snca multiplication kindreds 11
idiopathic PD, with no atypical features (Chartier-Harlin et al., 2004;
Ibanez et al., 2004). Duplication has also been documented in sporadic
PD and these cases are clinically indistinguishable from idiopathic PD
(Ahn et al., 2008; Ibanez et al., 2009).
However, more recent reports have described atypical features in
duplication cases, with variability within the same family (Nishioka
et al., 2006; Ahn et al., 2008). In a report of four duplication kindreds,
11 members presented with parkinsonism, six of whom developed
hallucinations or delusions and three developed dementia (Nishioka
et al., 2009). All kindreds had asymptomatic carriers, the oldest aged
79; the lifetime penetrance was estimated at 43.8%. A recent screen
found two patients with SNCA duplication who developed parkin-
sonism around the 5th decade, followed by rapid cognitive decline,
hallucinations and orthostatic hypotension (Shin et al., 2010). Neither
had any family history. The authors retrospectively reviewed 32 du-
plication patients and found cognitive dysfunction in one third. This
is comparable to the prevalence of dementia in sporadic PD, which
has been estimated to be between 24 and 31% of cases(Aarsland et al.,
2005). Autonomic involvement was seen in half – a similar prevalence
to that seen in triplication cases. The overall time course of disease
progression was also comparable to triplication cases, but with an
onset over two decades later.
The Swedish-American kindred also includes an individual with
SNCA duplication, presenting with orthostatic hypotension aged 71
and parkinsonism a year later, with frequent falls and urinary incon-
tinence, although tremor was very mild (Fuchs et al., 2007). Imaging
revealed significant reduction of dopamine transporter (DAT) in both
striata. The clinical diagnosis was MSA.
Four members of a Japanese SNCA duplication kindred developed
dopa-responsive parkinsonism, accompanied by dementia and visual
hallucinations during the late stages of the disease (Ikeuchi et al.,
2008). A further member developed parkinsonism aged 28, dementia
aged 35 and died aged 48: a disease trajectory similar to many trip-
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lication cases, including the premature onset. He was in fact found
to have homozygous duplication of SNCA, due to consanguinuity in
the family, and therefore had four copies of the gene, rather than the
three expected from a single duplication.
Clinical features of duplication cases are summarised in Table 1.3
(rigidity and bradykinesia were present in all cases). Overall, the data
from all of the multiplication kindreds demonstrate that gene dosage
of SNCA determines disease onset and the severity of progression,
rather than extent of the replicated region, which varies from kindred
to kindred (Ross et al., 2008a; Ibanez et al., 2009).
1.4 a-synuclein expression in sporadic pd
How might increased SNCA dosage be relevant to sporadic disease?
Postmortem sporadic PD brain tissue has a higher expression of a-
synuclein mRNA compared to controls (Chiba-Falek et al., 2006),
suggesting that a similar pathogenic mechanism might be responsi-
ble. Polymorphisms in the Rep1 complex repeat site (located in the
promoter region of SNCA approximately 10 kb upstream of the trans-
lational start of the gene) have been linked to sporadic PD (Kruger
et al., 1999; Tan et al., 2000; Farrer et al., 2001b; Maraganore et al.,
2006). A luciferase-based assay found a marked three-fold difference
in a-synuclein expression with different Rep1 alleles in SH-SY5Y cells
(Chiba-Falek and Nussbaum, 2001).
Moreover, associations have been found between Rep1 and levels of
a-synuclein protein in blood samples from PD patients (Fuchs et al.,
2008) and SNCA mRNA in control brain (Linnertz et al., 2009) whilst
SNCA mRNA varied 1.7-fold in transgenic mice carrying the different
Rep1 alleles (Cronin et al., 2009).
It is not yet known whether the higher expressing mice also have
a higher incidence of PD-type pathology, but nevertheless these data
1.4 a-synuclein expression in sporadic pd 13
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point to the possibility that sporadic disease is also caused by higher
expression of a-synuclein.
Indeed, genome wide association studies reveal that variation at
the SNCA locus is associated with sporadic PD (Satake et al., 2009;
Simon-Sanchez et al., 2009) and variation at this locus has also been
demonstrated in MSA (Scholz et al., 2009). In both of these studies, the
association signal localises to the 3’ end of SNCA and shows partial
linkage disequilibrium with Rep1, suggesting that these variants may
be different markers of a single causal variant, which likely affects
gene expression levels.
1.5 implications for a-synuclein pathogenesis
These clinical studies point to a striking dosage relationship between
a-synuclein and disease. Genetic variation in SNCA may well increase
risk of sporadic PD through increasing expression, whilst three copies
of the locus rather than the normal two can, in around half of indi-
viduals, lead to parkinsonism resembling idiopathic PD (albeit with
atypical features being more common). However, one additional copy
confers full penetrance of what is in most cases an early-onset con-
dition, with clinical features that can encompass PD, DLB and MSA.
Therefore, modest alterations in expression level are sufficient to cause
a wide spectrum of disease. Degeneration may be initially confined
to the nigrostriatal pathway, but as a-synuclein dosage increases, the
likelihood of more widespread pathology (e.g. cortical involvement in
DLB or glial and cerebellar involvement in MSA) increases in tandem.
Increased accumulation of a-synuclein is also seen with dysfunction
of several other PD genes. including LRRK2 and GBA, mutations in
which comprise the two commonest genetic causes of PD (Cookson,
2010; Velayati et al., 2010). Most cases of PD caused by mutations in
LRRK2 have a-synuclein pathology (discussed below in Section 1.7.1).
Previously, overexpression of mutant LRRK2 was seen to increase a-
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synuclein deposition and neurodegeneration in A53T transgenic mice,
perhaps explained by the observed impaired microtubule dynamics
and Golgi fragmentation increasing local concentrations of a-synuclein
in the soma, whilst knockout of LRRK2 was found to be protective
(Lin et al., 2009). However, recent contradictory data suggest that
neuropathology in the A53T mouse proceeds irrespective of deletion
of LRRK2 or overexpression of wildtype or G2019S mutant LRRK2
(Daher et al., 2012; Herzig et al., 2012), implying that the interaction is
more complex than previously thought, if it exists at all.
GBA encodes glucocerebrosidase, and mutations lead to a defi-
ciency of this protein. This in turn precipitates accumulation of its
substrate glucocerebroside, which has recently been shown to stabilise
oligomeric a-synuclein intermediates – permitting their conversion
into fibrils – whilst a-synuclein itself inhibits the normal lysosomal
activity of glucocerebrosidase, leading to further accumulation of
glucocerebroside, thus forming a pathogenic positive feedback loop
(Mazzulli et al., 2011).
Recessive mutations in parkin cause young-onset disease (Kitada
et al., 1998). Here too a mechanism increasing local concentrations of
a-synuclein may be responsible. Parkin encodes an E3 ubiquitin ligase
which provides specificity for the process of tagging proteins for degra-
dation in the proteasome (Shimura et al., 2000) and PD-associated
mutations disrupt this ligase activity (Tanaka et al., 2004). A glycosy-
lated form of a-synuclein has been shown to be a potential target of
this ligase activity (Shimura et al., 2001) although it remains unclear
whether this form is pathologically relevant. Furthermore, PD caused
by mutations in parkin generally cause nigral degeneration without
Lewy body pathology (Hardy et al., 2009), although Lewy bodies
have been reported in individuals with heterozygous mutations in this
gene (Farrer et al., 2001a; Pramstaller et al., 2005). Therefore perhaps
parkin mutations can also augment accumulation of a-synuclein via
impairing its degradation in the proteasome.
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Taking this clinical and genetic evidence together (summarised in
Figure 1.2), what can be inferred about the possible mechanisms of
a-synuclein-mediated pathogenesis?
1.5.1 Disruption of the normal role of a-synuclein
Synucleins are abundant neuronal proteins, enriched in presynap-
tic termini (Maroteaux et al., 1988), but their physiological role is
unknown. a-Synuclein knockout mice are normal, apart from exhibit-
ing increased release of dopamine from nigrostriatal neurons under
certain conditions, implying that the protein can negatively regulate
dopaminergic neurotransmission (Abeliovich et al., 2000). Given po-
tential redundancy between synucleins, this work was extended in
triple knockout mice lacking a-, b- and g-synuclein: here, a clear phe-
notype emerges of an age-dependent alteration in axonal morphology,
neuronal dysfunction and decreased survival (Greten-Harrison et al.,
2010).
Maintenance of protein complexes involved in synaptic release
requires chaperone activity mediated by synucleins; these protein
complexes are decreased in the abg-synuclein knockout mouse (Burré
et al., 2010). Subtle overexpression of a-synuclein in mice (in a range
similar to that seen clinically) impairs neurotransmitter release via
defective synaptic vesicle recycling, in the absence of overt toxicity
(Nemani et al., 2010). However, it remains to be seen whether this
functional perturbation can lead to neuronal loss over the time course
seen in PD.
a-Synuclein has been shown to bind to mitochondria, more so when
overexpressed, impairing complex I function, decreasing respiration
and increasing free radical production (Loeb et al., 2010; Chinta et al.,
2010). Expression of a-synuclein in mammalian neurons (both in vitro
and in vivo) leads to fragmentation of mitochondria (Nakamura et al.,
2011) whilst in cultured cells and in C. elegans, a-synuclein also causes
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Figure 1.2: Multiple pathways promote accumulation and aggregation of a-
synuclein. Gene multiplications and certain Rep1 polymorphisms
can increase expression of a-synuclein directly. On the other hand,
degradation of a-synuclein in the proteasome may be impaired by
parkin mutations. Mutated LRRK2 can fragment golgi, disrupting
vesicular trafficking and thereby increasing a-synuclein in the
soma. Mutations in glucocerebrosidase cause accumulation of
glucocerebroside, which stabilises oligomeric a-synuclein, enhanc-
ing fibril formation. In turn, a-synuclein impairs physiological
glucocerebrosidase function. Multiple environmental toxins, in-
cluding heavy metal cations, organic solvents and pes cides, can
enhance misfolding and aggregation of a-synuclein. However, it
is currently unclear what species of a-synuclein (oligomers or
fibrils) are toxic to cells.
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dysfunction of mitochondria (Kamp et al., 2010). These are pertinent
findings given the importance of mitochondria in maintaining neu-
ronal viability in PD (Knott et al., 2008; Henchcliffe and Beal, 2008).
Mice overexpressing the disease-associated A53T SNCA mutation de-
velop mitochondrial DNA damage and degeneration (Martin et al.,
2006), and a-synuclein pathology in this model is exacerbated by ex-
posure to paraquat (Norris et al., 2007). In contrast, dopaminergic
neurons in a-synuclein knockout mice are resistant to the neurotoxin
MPTP (Klivenyi et al., 2006).
Overexpression of a-synuclein has also been shown to impair au-
tophagy, a major route for clearance of aggregate–prone intracyto-
plasmic proteins, whilst a-synuclein depletion enhances this pathway
(Winslow et al., 2010). Overexpressing cells would also likely clear
dysfunctional mitochondria less efficiently, increasing susceptibility to
apoptotic stimuli. The combination of these perturbations, persisting
over many decades, might be sufficient to cause neuronal death.
1.5.2 Toxicity of a-synuclein
Fibrillogenic monomers of a-synuclein form oligomeric intermedi-
ates which assemble into fibrils, and finally deposit in Lewy bodies
(Schulz and Falkenburger, 2004). a-Synuclein has a strong tendency
to self-aggregate in vitro. Therefore, increasing its expression would
be expected to generate more of these aggregates (Uversky, 2007).
However, a pivotal question is which of these species, if any, are toxic
to neurons?
For example, there is a dissociation between presence of Lewy bod-
ies and cellular loss: Lewy bodies are present in 10-15% of individuals
over the age of 65 who die without clinical evidence of neurological
illness, despite having an identical pattern of deposition to that seen in
PD, although such cases may represent pre-clinical PD which would
manifest given time (Gibb and Lees, 1988). Cytotoxicity in model
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systems can occur without aggregated a-synuclein (Xu et al., 2002).
Lentiviral expression of a-synuclein in rat nigrostriatal neurons re-
sults in selective dopaminergic toxicity, but without fibrillar inclusions,
whilst missense mutations in SNCA (for example, A30P) increases
oligomerisation of a-synuclein, but not fibril formation (Conway et al.,
2000; Lo Bianco et al., 2002).
The mechanism of toxicity is not clear, but there are several hypothe-
ses, for example through disruption of membranes via the formation
of pores (Lashuel et al., 2002). Lewy body formation might, in fact, be
an adaptive cellular response, protecting neurons from the damaging
effects of oligomeric intermediates.
1.5.3 Permissive templating of a-synuclein
Transplantation of fetal dopaminergic neurons began over twenty
years ago as a potentially curative treatment for PD (Bjorklund et al.,
2003). Recently, several individuals with these transplants have come
to autopsy, with surprising results. Lewy body pathology is observed
in surviving nigrostriatal neurons, as expected. But in eight patients
who have received this treatment, Lewy bodies were observed in the
transplanted dopaminergic neurons as well (Kordower et al., 2008a; Li
et al., 2008; Kordower et al., 2008b). There are two possible explana-
tions for these findings:
1. Lewy body pathology arises de novo in these transplanted cells.
However, these grafts have all been less than 14 years old at the
time of autopsy, yet PD is a disease of old age. Is this not far too
early for such pathology to develop?
2. Alternatively, pathology spreads from the diseased host neurons
to the grafted cells, reminiscent of a prion-like process.
Prion diseases are characterised by spread of prion protein (PrP) from
one organism to another. Healthy cellular PrP (designated PrPC) is
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ubiquitously expressed and has the same amino acid sequence as
the disease-causing scrapie isoform (PrPSc) but a different secondary
structure, being composed largely of a-helices whilst PrPSc is predomi-
nantly b-sheets. Disease is caused by a change in conformation of PrPC
to PrPSc, which can act as a template for recruitment of PrPC, convert-
ing them into PrPSc. Aggregates of the disease isoform build up, and
propagate between cells leading to disease progression (reviewed by
Aguzzi et al. (2008)).
a-Synuclein is unstructured in aqueous buffers, whilst adopting a
predominantly a-helical structure when membrane bound, which can
become b-sheet when present at high concentration or in mutant form
(Conway et al., 1998). a-Synuclein is present in cerebrospinal fluid
and plasma of healthy subjects and patients with neurodegenerative
diseases (El-Agnaf et al., 2006; Noguchi-Shinohara et al., 2009), and
can be detected in media of neuronal culture models (Lee et al., 2005).
More specifically, exosomes released by a-synuclein overexpressing
SH-SY5Y cells contain a-synuclein and pharmacological inhibition of
lysosomal function increases this release (Alvarez-Erviti et al., 2011).
Recent studies have provided direct evidence of cell-to-cell spread:
neurons overexpressing a-synuclein can transmit the protein to neigh-
boring neurons in culture, and to neural precursor cells in a transgenic
model of PD-like pathology (Desplats et al., 2009) and also to postmi-
totic nigrostriatal neurons, in a direct model of the fetal transplantation
clinical studies (Hansen et al., 2011). Oligomers of a-synuclein can re-
cruit, and aggregate, a-synuclein endogenously expressed by primary
cortical neurons, and this effect increases with time and also with
concentration of the applied oligomers (Danzer et al., 2009). In other
words, misfolded a-synuclein might operate as a template catalysing
further misfolding events (Hardy, 2005).
Transmission of misfolded a-synuclein between cells provides a
mechanistic basis for the findings of Braak et al. (2003) where a-
synuclein pathology extends sequentially from the dorsal motor nu-
cleus in the lower brainstem, to upper brainstem areas and from there
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to the cerebral hemispheres. The authors speculate that PD pathology
may arise first in the nose and foregut, which act as portals for entry
of an unknown neurotropic pathogen, via inhalation or ingestion,
and suggest that this pathogen may trigger misfolding of a-synuclein
(Hawkes et al., 2007).
An alternative possibility is that an environmental toxin, rather than
a pathogen, is responsible. Many potential neurotoxins, including
metals, solvents, pesticides and herbicides have been linked to PD (re-
viewed by Uversky (2007)). Paraquat and rotenone enhance production
of a-synuclein in vivo, whilst in vitro, fibrillation of a-synuclein is dra-
matically accelerated by these and other substances, including heavy
metal cations and organic solvents. These can all induce structural
perturbations in a-synuclein and stabilise partially folded structures,
which are prone to form fibrils.
Increased SNCA expression could cause PD by augmenting the
likelihood of a-synuclein misfolding, the quantity of exocytosed mis-
folded proteins, and the speed of nucleation in recipient cells. Age is
the major risk factor for sporadic PD, and concentration of a-synuclein
increases with age in neuronal cell bodies (Chu and Kordower, 2007).
Therefore, in both SNCA multiplication and sporadic PD, initiation of
disease relates to and appears to be dependent on the concentration of
the pathogenic protein, perhaps through increasing the chances of a
misfolding species emerging, which could form a scaffold for further
proteins to misfold and aggregate.
a-Synuclein fibrillisation starts in vitro with a lag-phase during
which soluble oligomers form a nucleus, but once the nucleus forms,
aggregates grow rapidly (Wood et al., 1999). Therefore, the prediction
would be that permissive templating is efficient and less dependent
on the concentration of the protein than the initial misfolding event,
such that the process becomes self-propagating. This would explain
the variable age of onset of disease, even in triplication cases, given the
stochastic nature of protein misfolding. Recent data suggests that prion
propagation in vivo proceeds via two phases: an initial exponential
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phase not dependent upon levels of PrPC, followed by a plateau
phase prior to clinical onset, the duration of which is shortened as
endogenous PrPC levels are increased (Sandberg et al., 2011). The
authors suggest that toxicity is exerted by neither PrPC nor PrPSc but
via a toxic intermediate, generation of which requires conversion to
take place and is therefore dependent on local availability of PrPC. If a
similar mechanism is at work in the synucleinopathies, the implication
of increasing SNCA expression becomes clear: time to onset of disease
is shorter.
1.6 implications for disease-modifying pd therapies
Neither the physiological nor the pathogenic roles of a-synuclein are
fully understood. Nevertheless, the clinical, genetic and toxin studies
described above speak to the importance of a-synuclein concentra-
tion, and cell-to-cell spread, in driving disease onset and progression.
Therefore, strategies that seek to either deplete, or prevent spread, of
a-synuclein ought to be clinically beneficial.
A recent report of an inducible a-synuclein transgenic mouse model
of DLB showed that reducing a-synuclein expression triggered a re-
versal in pathological changes and improved behaviour and memory
(Lim et al., 2011). This provides proof of concept data that a-synuclein
depletion might not just slow disease progression, but in fact reverse
it.
However, it is not yet clear how this depletion should be achieved.
Several studies have employed RNA interference to successfully re-
duce a-synuclein expression in cells (Fountaine et al., 2008), rodents
(Sapru et al., 2006; Lewis et al., 2008) and primates (McCormack et al.,
2010), although reversal of pathological changes has not been demon-
strated with this approach so far. Moreover, a-synuclein silencing
caused nigral degeneration in rat (Gorbatyuk et al., 2010), precisely the
opposite effect of that desired. The reasons for this are not certain,
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and seem at odds with SNCA knockout mouse models that are rel-
atively normal (Abeliovich et al., 2000). Nevertheless, given that in
vivo levels of a-synuclein are likely to be tightly regulated, perhaps
the goal should be normalisation of a-synuclein levels rather than full
suppression.
There is also the wider problem of turning such antisense strate-
gies into viable drugs. Problems with degradation of the introduced
oligonucleotides, and off-target effects are commonly seen (Jones,
2011), notwithstanding the considerable difficulties of delivering such
an agent into the brain.
Enhancing degradation of a-synuclein protein might be a viable pos-
sibility. Pharmacological upregulation of autophagy has been shown to
help clear the protein, for example (Sarkar et al., 2007). Antibody-based
strategies also look promising. Vaccination of human a-synuclein-
expressing mice with human a-synuclein protein led to degradation
of aggregates of human a-synuclein, a reduction in formation of new
aggregates, and diminished neurodegeneration (Masliah et al., 2005).
Indeed, the presence of autoantibodies directed against a-synuclein
has recently been reported in PD patients, and antibody titres re-
duce with progression of disease, implying that immune-mediated
clearance of a-synuclein may be a factor in determining disease onset
(Yanamandra et al., 2011).
Much current work focuses on a-synuclein depletion as a possi-
ble therapeutic strategy. However, when we consider the ascending
pathology noted by Braak et al. (2003), the spectrum of pathology
seen in the multiplication kindreds, and the presence of Lewy bod-
ies in grafted fetal dopaminergic neurons, then cell-to-cell protein
propagation begins to take on a central role in the disease process.
The mechanistic basis for this propagation has not yet been fully
defined. Nor is it known whether it serves a physiological purpose.
Nevertheless, blocking it is an attractive potential therapeutic target.
This strategy may help preserve brain areas not yet affected by the
pathological process, if potentially toxic forms of a-synuclein are pre-
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vented from reaching them. It might also avoid potential side effects of
excessive a-synuclein depletion. However, it remains possible that cel-
lular release of a-synuclein might be a mechanism by which cells can
lower concentrations of this protein before they become dangerously
high. Therefore, it is conceivable that the combination of a-synuclein
depletion with blockade of its propagation will be required to make a
clinically detectable impact on disease progression. We therefore need
strategies that normalise a-synuclein levels rather than fully deplete it,
and are deliverable intrathecally. In addition, we need to understand
precisely how, and importantly why, a-synuclein propagates from cell
to cell, in order to appropriately target it.
1.7 the role of lrrk2 in pd
Mutations in LRRK2 (leucine-rich repeat kinase 2) were established
as an autosomal dominant cause of familial PD in 2004 (Paisan-Ruiz
et al., 2004; Zimprich et al., 2004). LRRK2 mutations are currently
regarded as one of the commonest genetic causes of PD, accounting
for 2 to 4% of all PD cases (Bonifati, 2006). The phenotype of PD
caused by mutations in LRRK2 is very similar to sporadic disease,
with similar age at onset, clinical presentation, rate of progression,
pathological features and response to l-dopa, suggesting that there
may be a shared aetiology (Khan et al., 2005). Furthermore, genome
wide association studies suggest that common variation at the LRRK2
locus influences the development of sporadic PD: a European cohort
study is supportive of a link (Simon-Sanchez et al., 2009) whilst a
Japanese cohort study found a significant link (Satake et al., 2009).
Taken together, studying the impact of LRRK2 mutations should help
us understand the pathogenesis of sporadic disease, given the strong
similarities between the two.
LRRK2 encodes a member of the ROCO family of proteins, contain-
ing a ROC (Ras of complex proteins)/GTPase, COR (C-terminal of
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Figure 1.3: LRRK2 ideogram. Mutations associated with disease are shown.
ANK, ankyrin repeats; LRR, leucine rich repeats; ROC, Ras of
complex proteins; COR, C-terminal of ROC. Adapted from Hardy
et al. (2009).
ROC) and a kinase domain, flanked by several protein-protein inter-
action motifs including a WD40 domain and Leucine Rich Repeats
(Marin, 2006). Figure 1.3 shows an ideogram of LRRK2 depicting the
domains and the sites of pathogenic mutations. The precise physiolog-
ical role of LRRK2 is unknown, and mutations associated with PD can
be found throughout the length of the gene, although there is a degree
of clustering within the enzymatic domains (Paisán-Ruíz et al., 2008),
and these appear to be the ones that exhibit penetrance (Ross et al.,
2011). In vitro studies suggest that mutations in the GTPase domain
and the COR domain decrease GTPase activity, whilst most mutations
in the kinase domain increase kinase activity (reviewed by Cookson
(2010)).
The three dimensional structure of full length LRRK2 is not known,
although the crystal structure of the ROC domain suggests that LRRK2
is a dimer, supported by evidence from cellular studies (Deng et al.,
2008; Greggio et al., 2008). LRRK2 associates with membranous struc-
tures including the mitochondrial outer membrane, as well as lysoso-
mal vesicles and punctate structures within the perikarya, dendrites
and axons (Biskup et al., 2006; Hatano et al., 2007). It is also found in
association with Golgi apparatus, plasma membranes and synaptic
vesicles.
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Studies of LRRK2 in rat neurons suggest a physiological role in
the regulation of neurite process morphology (MacLeod et al., 2006).
Expression of G2019S LRRK2 in SH-SY5Y cells leads to neurite short-
ening associated with increased autophagic vacuole content, whereas
RNA knockdown of autophagy-relevant proteins or interference with
the MAPK/ERK signalling pathway reverses this phenotype (Plowey
et al., 2008). LRRK2 interacts with parkin (recessive mutations in
which cause juvenile parkinsonism) in vitro but not a-synuclein or tau
(Smith et al., 2005). The ROC domain has been shown to be capable
of interacting with b-tubulin, a key component of microtubules, and
moesin (Jaleel et al., 2007; Gandhi et al., 2008). Of more apparent
relevance is a possible interaction with a-synuclein: Qing et al. (2009)
have shown that recombinant LRRK2 is capable of phosphorylating
a-synuclein in vitro, and G2019S mutant LRRK2 even more so. In vivo
studies are required to clarify all of these findings, but these data
nevertheless suggest interactions with pathways already implicated in
PD pathogenesis.
1.7.1 Tau, tangles and tauopathies
Although patients with mutations in LRRK2 have in general a uniform
phenotype that closely resembles sporadic PD, a remarkable feature
of these cases is that they display highly variable pathology. Two cases
from a clinically uniform R1441C kindred displayed respectively Lewy
body pathology typical of PD and a Lewy body distribution similar
to DLB, whereas a third case had no observable protein deposition
(Zimprich et al., 2004). A fourth case displayed a different pathology al-
together: neurofibrillary tangles (NFTs) in a pattern similar to that seen
in progressive supranuclear palsy. Cases with the G2019S mutation
have variably shown either Lewy body pathology, or NFT pathology
(Rajput et al., 2006). This holds true for cases with the Y1699C muta-
tion and a case with the I1371V mutation (Khan et al., 2005; Giordana
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et al., 2007). Four members of the original Japanese kindred, carry-
ing the I2020T mutation, displayed nigral cell loss without distinct
pathology (Funayama et al., 2005). More recently, inclusions of TDP-43
(TAR DNA binding protein 43) have been found at post mortem in
individuals with LRRK2 PD: Covy et al. (2009) report such inclusions
in the temporal cortex (though not elsewhere) in two patients with
tangle-predominant DLB, whilst Wider et al. (2010) report these inclu-
sions in a patient with otherwise pure nigral degeneration. TDP-43 is
a major constituent of intracellular inclusions seen in patients with
frontotemporal lobar degeneration (Neumann et al., 2006).
NFTs are aggregates of the protein tau, encoded by MAPT (micro-
tubule-associated protein tau, in full). In 1998, mutations in MAPT
were linked to frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), providing a direct link between tau and
pathogenesis in these cases (Hutton et al., 1998). Just as the synucle-
inopathies (PD, DLB and MSA) are defined by intracellular aggregates
of a-synuclein, the tauopathies – comprising PSP, corticobasal degener-
ation (CBD), and frontotemporal dementia (FTD) – are defined by tau
deposition. The heterogeneous nature of LRRK2-associated pathology
has led to the suggestion that LRRK2 may link tau and a-synuclein by
operating upstream of their respective pathological cascades.
Tau is a microtubule-associated protein that is abundant within
the central nervous system and exists as six alternatively spliced
isoforms (Andreadis, 2005). Tau stabilises microtubules by promoting
their polymerisation and suppressing their dissociation, and appears
to have a stabilising role during axonal outgrowth (Ballatore et al.,
2007). Suppression of tau expression decreases neurite formation, with
ectopic expression of tau leading to growth of axon-like structures. Tau
isoforms differ by the number of microtubule binding domains that are
present. It is an abundantly phosphorylated protein: phosphorylation
has been reported at 30 out of a possible 70 serine and threonine
residues.
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Akin to amyloid formation by a-synuclein, tau can aggregate to
form paired helical filaments, which are deposited in NFTs. Several
lines of evidence suggest that oligomeric tau is the toxic species, rather
than NFTs themselves (Iqbal et al., 2005). NFT-bearing neurons can sur-
vive for decades and there is no apparent causal relationship between
apoptotic morphology and tau deposition. In D. melanogaster, retinal
degeneration is observed with tau expression alone, and neuronal
death can be seen without NFTs (Wittmann et al., 2001). Suppressing
tau expression in a mouse model of FTDP-17 improves memory func-
tion and stabilises neuronal numbers, despite the continued presence
of tangles (Santacruz et al., 2005).
The role of phosphorylation is a critical aspect of the biology of
tau. Increased phosphorylation of tau negatively regulates its bind-
ing to microtubules and tau is hyperphosphorylated in the paired
helical filaments that form NFTs. MAPK activation due to oxidative
stress leads to phosphorylation of tau (Zhu et al., 2000). Following
hyperphosphorylation, tau dissociation from microtubules increases
the concentration of soluble tau, enhancing its propensity to aggre-
gate (Garcia de Ancos et al., 1993). Mutations in tau cause disease by
impacting on alternative splicing, or point mutations that impair the
ability of tau to bind to microtubules.
In addition to the pathological parallels between tau and a-synuclein,
there is significant overlap at the genetic and clinical levels. Tauopathies
often have parkinsonian features, whilst synucleinopathies can present
with dementia (Galpern and Lang, 2006). Both tau and a-synuclein
inclusions have been reported in some disease cases, with Lewy bodies
and NFTs sometimes present in the same cell. In the Contursi kindred,
carrying the A53T SNCA mutation, tau inclusions were observed in
some individuals, in addition to Lewy bodies (Duda et al., 2002).
Furthermore, an increase in the overall burden of tau can also cause
disease: the H1 haplotype (which increases transcription of tau) pre-
disposes to tauopathies (Kwok et al., 2004). In vitro, a-synuclein binds
tau, can stimulate its phosphorylation, and initiate its polymerisation
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(Jensen et al., 1999; Giasson et al., 2003). Both proteins can synergisti-
cally aggregate to form homopolymers. There is also an interaction
in animal models of disease: bigenic mice overexpressing a-synuclein
and tau display exacerbated pathologies for both proteins compared
to the monogenic equivalents (Giasson et al., 2003). Finally, a syn-
ergistic interaction between tau and a-synuclein has been shown in
the development of cognitive impairment in PD patients, where the
combination of the MAPT inversion polymorphism and a single nu-
cleotide polymorphism (SNP) in SNCA doubles the risk of developing
cognitive impairment, whereas either alone only marginally increases
risk (Goris et al., 2007).
1.7.2 LRRK2 and pathogenesis
The G2019S mutation in the kinase domain of LRRK2 has been shown
to increase its activity, whilst mutations in the ROC domain disrupt
GTPase activity or increase its affinity for GTP (West et al., 2005;
Lewis et al., 2007; Li et al., 2007). The Y1699C mutation in the COR
domain has recently been shown to decrease GTPase activity as well
(Daniëls et al., 2011). These studies are consistent with a model where
the GTPase domain regulates the activity of the kinase domain, with
mutations acting to increase the activity of the latter (West et al., 2007).
However, not all the experimental data fits with this model: mutations
outside of the kinase domain do not consistently raise kinase activity
by in vitro assay (Greggio et al., 2006), and the G2385R mutation,
a known risk factor for PD located in the WD40 domain, causes a
partial loss of kinase function (Rudenko et al., 2012). It is possible
that mutations in the COR domain alter the spatial relationship, and
therefore the interaction, between the ROC and kinase domains, and
that mutations in the protein/protein interaction domains change
binding to substrates or regulatory proteins, but more structural data
or physiological substrates are needed to examine this.
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What is becoming clear is that the enzymatic activities of LRRK2
play a central role in disease. For example, LRRK2 mutants are less
cytotoxic if the GTP binding or kinase activity of LRRK2 is artifi-
cially ablated (Greggio et al., 2006; Smith et al., 2006). Mirroring the
aggregation seen with a-synuclein and tau, there is some evidence
that LRRK2 may also aggregate and form inclusions. When LRRK2
is overexpressed in some cells, the protein can form inclusion bodies
that are exacerbated if carrying mutations, and LRRK2 has been found
in Lewy bodies in sporadic PD (Greggio et al., 2006).
There are clear pathogenic links between mutations in MAPT or
SNCA and familial PD. Furthermore, genetic variability at these loci
are also associated with sporadic disease. Genome wide analysis
of sporadic PD has demonstrated linkage to chromosome 17 in the
MAPT region (Scott et al., 2001). The A0 MAPT allele (Pastor et al.,
2000) and H1 haplotype (Martin et al., 2001; Healy et al., 2004) are
overrepresented in the context of sporadic PD. Meanwhile, SNCA is a
clear susceptibility gene for sporadic PD, as described in Section 1.4.
Similarly, the LRRK2 G2019S mutation is significantly more common
in patients with sporadic PD than in controls (Hulihan et al., 2008),
with an overall prevalence of 1% in cases of sporadic PD, and 4%
in hereditary PD. Furthermore, the common genetic LRRK2 variants
G2385R and R1628P both increase the risk of developing sporadic PD
in Chinese populations (Tan, 2007; Ross et al., 2008b).
Taken together, these findings suggest that the distinction between
sporadic and familial disease is somewhat arbitrary. The extremes of
fully penetrant genetic and apparently sporadic PD should be consid-
ered opposing ends of a spectrum. Most cases of PD will result from
a combination of environmental and genetic factors, underlining the
importance of genetic findings in understanding how sporadic disease
develops. Intriguingly, as yet there is no documented link between
LRRK2 and tauopathies or synucleinopathies presenting without pure
parkinsonism, for example AD (Toft et al., 2005), PSP (Ross et al.,
2006) or MSA (Ozelius et al., 2007). It is not known whether variation
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in LRRK2 alter the likelihood of developing these diseases – there is
no evidence for a direct autosomal dominant causative relationship
– but it would be possible to rationalise such a connection given the
unpredictable nature of LRRK2 PD pathology. Future genome-wide
association studies might bring some clarity to this issue.
1.7.3 A pathogenic troika
Individually, mutations in SNCA andMAPT lead to parkinsonism and
dementia characterised by protein deposition in Lewy bodies and NFTs
respectively, whereas mutations in LRRK2 generate PD coincident with
a-synuclein or tau pathology. In light of the evidence linking LRRK2
kinase dysfunction to disease, an attractive hypothesis is that tau
and a-synuclein are downstream targets of this activity, linking in to
the dysregulation of the phosphorylation state of these proteins. As
yet, however, firm experimental evidence for this is lacking: there is
a report of abnormally deposited and phosphorylated tau in a rat
neuronal cell model (MacLeod et al., 2006), and LRRK2 appears to be
capable of phosphorylating a-synuclein at Serine 129 (G2019S mutated
LRRK2 even more so) in a transfected HEK 293T model (Qing et al.,
2009). Based upon the genetic evidence, where a-synuclein and tau
are capable of causing disease independent of mutations in LRRK2,
with tau also reacting to deposition of Ab in AD, the data suggest that
there are separate, yet interlinked, pathways in operation (Figure 1.4).
One of the most perplexing aspects of LRRK2 pathobiology is how
identical mutations in the same kindred can generate different patholo-
gies. There are several hypotheses, which are not mutually exclusive,
for why this might occur, as follows.
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Figure 1.4: The parallel and interlinking pathways between tau, a-synuclein
and LRRK2 neurodegeneration linked to parkinsonism and de-
mentia, showing the potential crosstalk between LRRK2 and
pathology associated with tau and a-synuclein dysfunction.
1.7.4 Impact of genetics
Outside of the context of LRRK2 disease,MAPT haplotypes and SNCA
expression levels are known to alter the likelihood of developing cor-
responding tau or a-synuclein pathology, so the simplest explanation
would be that genetic variability at these loci determine resulting
pathology. The other possibility is that as yet undetermined gene or
genes play a regulatory role, perhaps by providing an interface for
crosstalk between the three pathways of LRRK2, tau and a-synuclein
(Figure 1.4). So far, the number of LRRK2 cases that have come to
autopsy is too small to study for potential genetic modifiers, but this
should become tractable with time given the prevalence of mutations.
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1.7.5 Impact of environment
Twin studies have suggested that non-genetic factors play a major
part in the development of PD. Epidemiological data have suggested
several possibly environment-linked factors that affect the likelihood
of developing PD, including pesticides, farming and head trauma
(Chade et al., 2006; Ascherio et al., 2006). There are also examples from
other neurodegenerative diseases. Repetitive head trauma can lead
to a dementing state both clinically and pathologically similar to AD,
termed dementia pugilistica (Schmidt et al., 2001). Subacute sclerosing
panencephalitis (SSPE), which presents with NFT pathology, can arise
as a rare late complication of infection with measles (Bancher et al.,
1996).
Therefore, different environmental factors might steer LRRK2 ei-
ther towards tau or a-synuclein pathology. There are two potential
difficulties with examining this hypothesis. Firstly, many of the epi-
demiological reports on PD do not describe the neuropathology of
the cases studied, and so it is currently tricky to build a model link-
ing specific pathologies with specific environmental insults. Secondly,
diseases with environmental links previously viewed as robust have
been called into question. For example, the parkinsonism-dementia
complex of Guam (NFT pathology) is now no longer felt to be due
to Cycad exposure (Steele and McGeer, 2008). Encephalitis lethargica
(another NFT disease) was originally thought to be a consequence
of influenza, because an outbreak occurred contemporaneously with
an outbreak of Spanish influenza in the early 20th century, though
opinion has since diverged (McCall et al., 2008). What is certain is
that it will require large numbers of cases of LRRK2 PD with neu-
ropathological correlation and extensive clinical and biographic details
to establish any environmental links with certainty.
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1.7.6 LRRK2 PD as a separate disease entity
I have discussed evidence that suggests at least some mutations in
LRRK2 can dysregulate the protein’s kinase activity. But LRRK2 may
convey pathology via other mechanisms: for example, wildtype but not
mutated LRRK2 can attenuate stress-induced cell death via activation
of the ERK pathway in a cell model (Liou et al., 2008), building upon
previous work which found that phosphorylation of proteins on the
ERK pathway was reduced in leucocytes carrying the G2019S mutation
(White et al., 2007).
These findings each shed light on separate, though not mutually
exclusive, mechanisms through which LRRK2 might convey toxicity.
One possible consequence is that the relative balance between LRRK2
gain of function (via kinase dysregulation) and loss of function (via
ERK pathway inactivation for example) determines the pathology
that results. The demonstration of phosphorylation and deposition
of tau in diseases that are not classically regarded as neurodegener-
ative (e.g. secondary progressive multiple sclerosis (Anderson et al.,
2008)) suggests that tau pathology might be a relatively generic, or
default, pathway to neuronal death. On the other hand, a-synuclein
pathology might require more stringent provocation. Therefore, one
might predict that tau pathology results from LRRK2 loss of function,
and a-synuclein pathology from LRRK2 gain of function. Genetic and
environmental modifiers would determine which of these prevails.
However, how can we account for cases where no specific pathol-
ogy is seen, for example in I2020T mutation cases? Perhaps in these
circumstances neurons die before typical tau or a-synuclein pathology
can be generated, with a predominance of protofibrils rather than
mature aggregates, in which case a further prediction would be that
these cases generally have a younger clinical onset of PD and a more
rapid clinical course. Current epidemiological data are insufficient to
draw conclusions on this.
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An alternative possibility is that any observable neuropathology
is an epiphenomenon, and that deranged LRRK2 drives neuronal
death through a separate pathway. LRRK2 has also been linked to
leprosy (Zhang et al., 2009) and Crohn’s disease (Franke et al., 2010)
via genome wide association studies. Furthermore, LRRK2 has been
found to be genetically amplified or overexpressed in cases of papillary
renal cell carcinoma and thyroid cancer (Looyenga et al., 2011). These
studies certainly hint at LRRK2 dysfunction having a broad impact on
cell regulation, potentially through multiple pathways.
Given evidence that neither tau nor a-synuclein accumulation and
aggregation directly correlates with neuronal death, perhaps LRRK2
can steer pathology without the help of the other members of the
troika. In any case, it does suggest that the correlation between clinical
phenotype and genotype is more robust than that between phenotype
and neuropathology. Returning to the therapeutic standpoint, clarifica-
tion of which of these possibilities is pivotal, because these hypotheses
suggest that attenuating dysregulated LRRK2 kinase activity may not
be sufficient to limit development of PD, at least in some cases.
1.7.7 The complexity of PD pathogenesis
PD pathogenesis is not a simple, linear pathway, universally trig-
gered by a single event. Instead, akin to cancerous cells developing
malignant potential through accumulation of several carcinogenic mu-
tations, there may be a requirement for multiple insults to occur before
dopamine neuron loss ensues. These can be divided into neuronal
stressors (e.g. oxidative) and diminished compensatory responses (e.g.
impairment of the proteasomal pathway). The age-related increase in
both PD prevalence, and LRRK2 penetrance, are consistent with this
view.
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There are three fundamental aspects of LRRK2 in particular that
need to be clarified in order to understand its role in PD pathogenesis
more completely:
1. the in vivo substrates of LRRK2, so that we can begin to work
out which intracellular pathways it maps to,
2. the structure of LRRK2, so we can begin to comprehend how it
interacts with these pathways,
3. the means by which LRRK2modifies tau and a-synuclein biology
specifically.
Understanding how the pathogenic mutations in LRRK2 impact upon
these three characteristics should aid the development of mechanistic
therapies for PD.
1.8 the need for new cell models
The biggest barrier to research on neurological disease is the inaccess-
ability of diseased tissue. Moreover, by the time PD manifests clinically
most of the cells of interest – midbrain dopaminergic neurons – have
already been lost (Kempster et al., 2010). Animal models allow the
study of PD in an intact organism, and much of our understanding
of the dopamine networks downstream of the substantia nigra has
come from studying toxin or lesion models of PD (Carlsson et al., 1957;
Langston et al., 1984). These models are very successful at modelling
loss of cells in the substantia nigra or depletion of dopamine, but rely
upon an acute insult to the nervous system and do not model the slow
degeneration observed in PD (Westerlund et al., 2010).
Following the description of mutations linked to familial PD, a num-
ber of transgenic models have been created, including D. melanogaster,
yeast and murine models of a-synuclein pathology (Feany and Bender,
2000; Outeiro and Lindquist, 2003; Masliah et al., 2005). These models
have shed light on the pathogenic processes operating in PD, but
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have been disappointing with regard to replicating the phenotype
and pathology of the human disease (Dawson et al., 2010). Indeed,
neither D. melanogaster nor S. cerevisiae has a gene that is homologous
to human SNCA, limiting their potential as models of PD.
Cellular models can circumvent some of these issues, but existing
primary and tumour cell models have major drawbacks. Primary neu-
ronal cultures from mice or rats are difficult to maintain in vitro and
do not self renew, and have an amino acid at position 53 of a-synuclein
which in humans causes disease (Larsen et al., 2009). Transformed
cell lines are readily amenable to genetic manipulation for study of
proteins of interest. However, these cells carry mutations in genes
that are involved in apoptosis and chromosomal rearrangements that
can disrupt cell signalling pathways, and are phenotypically different
from the cells affected by the disease process – all of which severely
limits their use as a model system (Bottomley et al., 1969; Jakel et al.,
2004; Gibbs and Singleton, 2006). A cellular environment that is so
far removed from that seen in disease hampers attempts to identify
genuine substrates of physiological and pathological LRRK2 activity
for example. It should also be noted that many of the existing cellular
models rely on poorly controlled overexpression of transgenes, a par-
ticular drawback when attempting to model a disease in which gene
dosage is a critical aspect, as seen in SNCA multiplication kindreds
(Eriksen et al., 2005).
1.9 pluripotent stem cells offer a possible solution
1.9.1 The discovery of pluripotent stem cells
Given that the zygote of multicellular animals differentiates into all the
cell lineages of the embryo and ultimately the adult, it was theorised
that cells must exist at early stages of development that have the
potential to differentiate into a wide range of cell lineages, a feature
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called pluripotency (from Latin pluri - many, and potens - having
power). Evidence for such pluripotent cells came from studies with
mouse teratocarcinomas – tumours that contain a large variety of
differentiated cell types. The demonstration that transplantation of a
single teratocarcinoma cell in vivo could result in a teratocarcinoma in
the recipient animal established the presence of pluripotent tumour
stem cells – stem referring to the property of self-renewal. These cells
were named embryonal carcinoma (EC) cells (Kleinsmith and Pierce,
1964). They could be established in culture, and also had the ability
to contribute to the formation of chimaeric mice (Papaioannou et al.,
1975). By this time it was thought that EC cells might not be grossly
abnormal cells, but rather normal early embryonic cells that find
themselves out of context.
Evans and Kaufman (1981) were the first to report the establishment
of defined early embryonic cells in culture, isolated from the inner
cell mass (ICM) of delayed blastocysts. These shared all properties
described for EC cells hitherto, in that they could be proliferated indef-
initely in culture, they would not senesce and they would retain their
pluripotency. Unlike EC cells, they also retained a normal karyotype.
The term embryonic stem (ES) cell was coined.
The ability of these cells to contribute to chimaeric mice was sub-
sequently demonstrated (Bradley et al., 1984). They chimaerised not
just the soma, but also the germline, hence genetic manipulation of
transferred ES cells could alter the genome of subsequent generations,
permitting the development of transgenic animals (Evans, 2008).
It was over a decade later that cells with equivalent properties
were derived from human embryos (Thomson et al., 1998), designated
human ES or hES cells.
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1.9.2 Nuclear reprogramming
In parallel with the work leading up to the discovery of ES cells, Sir
John Gurdon showed that it was possible to generate new animals by
transferring tadpole intestinal cell nuclei into enucleated eggs from the
African clawed toad, Xenopus laevis (Gurdon, 1962). By some means
yet to be fully worked out, the recipient egg had reprogrammed the
nucleus from the donor differentiated cell, enabling the development
of a normal embryo, genetically identical to the donor. These seminal
findings paved the way for nuclear reprogramming (as this technique
was called) to be applied to mammalian adult cells, with the cloning
of Dolly the sheep (Wilmut et al., 1997).
The paths of nuclear reprogramming and ES cell biology crossed
with a report in 2001 that thymocytes would acquire pluripotency on
electrofusion with mouse ES cells (Tada et al., 2001). Therefore, ES
cells also have the capability to reprogram nuclei – ES cells as well as
eggs contain factors that induce pluripotency in somatic cells.
1.9.3 Induced pluripotent stem cells
The discovery that eggs and ES cells could reprogram differentiated
nuclei led Shinya Yamanaka to hypothesise that it might be possible to
induce pluripotency in somatic cells using factors that are responsible
for maintaining the pluripotent cell state (Yamanaka, 2009). Over sev-
eral years, his lab assembled a list of factors that are either specifically
expressed in mouse ES cells, or have important roles in these cells. By
2004, a total of 24 candidate genes had been curated.
Through an intelligent process of elimination, this list was swiftly
wittled down to just four genes that, when overexpressed in fully
differentiated mouse cells, could convert them into a pluripotent stem
cell state, a groundbreaking result reported in 2006 (Takahashi and
Yamanaka, 2006). The cells produced were termed induced pluripotent
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stem cells (iPS cells or iPSCs). Those four factors were Oct4, Sox2, c-
Myc and Klf4 – all transcription factors known to have important roles
in the pluripotency gene network. The first reports of the generation
of human iPSCs came the following year from several groups working
independently: Yamanaka’s team achieved reprogramming of human
somatic cells with the same four factors that worked in mouse (Taka-
hashi et al., 2007b); Jamie Thomson’s group, working on the same
problem almost in parallel, found that a slightly different combination
(Oct4, Sox2, Lin28 and Nanog) also works (Yu et al., 2007); George
Daley’s group supplemented the Yamanaka four factor cocktail with
SV40 large T and hTERT (Park et al., 2008b).
1.9.4 A new model system
iPSC technology thus makes it feasible to take fully differentiated cells
from humans and reprogram them to adopt a pluripotent state. When
applied to the modelling of disease, the ramifications of this become
clear: the specific cells affected by disease can be generated that bear
the same gene mutations that cause the disease. For example, midbrain
dopaminergic neurons bearing mutations in SNCA or LRRK2 could
be generated from patients with PD caused by these mutations. This
technology has the potential to revolutionise our understanding of PD
precisely because it provides the opportunity to generate and study
disease-affected cells directly from patients.
The iPSC-based approach to disease modelling was rapidly adopted
and by the end of 2009 had been employed to generate cell models
for several neurological conditions. Dimos et al. (2008) published
an early study demonstrating that it is feasible to generate iPSCs
and thence motor neurons from an elderly patient with amyotrophic
lateral sclerosis (ALS) carrying a mutation in SOD1, although a cellular
phenotype was not reported. Soldner et al. (2009) generated iPSC lines
from five patients with sporadic PD; dopaminergic neurons could be
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differentiated from all cell lines examined. Ebert et al. (2009) generated
two iPSCs from a patient with spinal muscular atrophy and Lee et al.
(2009) described an iPSC model of familial dysautonomia.
Although few if any of these reports described clear phenotypic dif-
ferences between cells derived from patients and healthy controls, they
provided important proof of principle that cells affected by disease
could indeed be derived from patients.
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1.10 thesis structure
This thesis begins by describing two studies in a fibroblast model of PD
caused by mutations in LRRK2. The first study provides preliminary
data on abnormal phosphorylation of 4E-BP (a component of the
mTOR pathway), and the second describes microarray analysis of
gene expression in LRRK2 mutation and control fibroblasts.
The next part of the thesis describes the different strategies that were
employed to attempt reprogramming of fibroblasts into iPSCs. I then
describe methods used to characterise iPSCs generated from members
of the Iowa SNCA triplication kindred. The final section documents
the approach used to direct differentiation of these iPSC lines into
midbrain dopaminergic neurons. This includes the demonstration that
neurons derived from a PD patient with triplication of SNCA contain
twice as much a-synuclein protein as those from a healthy relative.
This doubling of a-synuclein recapitulates the cause of PD in members
of this kindred. The advantages and limitations of this model system
are discussed, in the context of the strong parallels that exist between
disease due to multiplication of SNCA, and sporadic PD. The thesis
concludes with an outline of potential future directions for this work.
Part II
F IBROBLASTS
In this section, I describe two studies in Parkinson’s dis-
ease patient fibroblasts with mutations in LRRK2. The first
examines a potential substrate of LRRK2 kinase activity,
and the second examines genome-wide gene expression in
these fibroblasts. Potential limitations of using fibroblasts
as a model of a neurological disease are discussed.
2
LRRK2 F IBROBLAST STUDIES
2.1 introduction
As outlined in Chapter 1, mutations in LRRK2 are currently regarded
as one of the commonest genetic causes of PD (Bonifati, 2006) and
phenotypically, PD caused by mutations in LRRK2 is very similar
to sporadic disease (Khan et al., 2005). Furthermore, genome wide
association studies suggest that common variation at the LRRK2 locus
influences the development of sporadic PD (Simon-Sanchez et al.,
2009; Satake et al., 2009). Therefore, studying the impact of LRRK2
mutations should help us understand the pathogenesis of sporadic
disease.
LRRK2 containes a ROC (Ras of complex proteins)/GTPase domain,
a COR (C-terminal of ROC) domain and a kinase domain, flanked by
several protein-protein interaction motifs including a WD40 domain
and Leucine Rich Repeats (Marin, 2006). The precise physiological role
of LRRK2 is not understood, and pathogenic mutations are clustered
within the enzymatic domains (Paisán-Ruíz et al., 2008). In vitro studies
suggest that mutations in the GTPase domain and the COR domain
decrease GTPase activity, whilst most mutations in the kinase domain
increase kinase activity (reviewed by Cookson (2010)). The presence
of these enzymatic domains, and the alteration of enzymatic activity
secondary to pathogenic mutations, has prompted the suggestion that
LRRK2 can act as a signaling node within cells, with the protein-
protein interaction domains functioning as scaffold areas to recruit
targets to an active protein complex (Hsu et al., 2010b). Specifically,
LRRK2 has been implicated in several signalling pathways including
44
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ERK signalling and the mTOR pathway (Hsu et al., 2010a; Imai et al.,
2008).
In order to try and identify phenotypic differences specific to LRRK2
mutation fibroblasts, I carried out experiments in fibroblasts obtained
from patients with LRRK2 PD. Results of such investigations have
the potential to help shed light on the pathogenic impact of these
mutations, and guide future experiments on iPSC-derived neurons.
Two experiments on fibroblasts are described in this chapter: the
study of the mTOR pathway member 4E-BP as a potential phospho-
substrate of LRRK2, and a comparison of gene expression in LRRK2
mutation and control fibroblasts.
2.1.1 4E-BP as a putative substrate of LRRK2
Studies in transfected HEK 293T cells and a D. melanogaster model
have suggested 4E-BP as a putative target of human LRRK2 and
D. melanogaster LRRK kinase activity respectively (Imai et al., 2008).
4E-BP is a downstream target of mammalian target of rapamycin
(mTOR), which is a central regulator of cell growth and proliferation
and acts mainly through the modulation of protein synthesis. It does
this in part by regulating protein translation, which permits cells
to respond swiftly to intrinsic and environmental stress. The PI3K
and Akt pathways integrate a wide range of signals from within and
outside the cell to modulate mTOR activity (reviewed by Hay and
Sonenberg (2004)).
4E-BP negatively regulates cap-dependent protein translation via
direct sequestration of eIF4E, part of the translation initiation complex.
Phosphorylation of 4E-BP causes its dissociation from eIF4E thereby
relieving inhibition. Thus the proposed phosphorylation of 4E-BP
by LRRK2 would prompt eIF4E liberation and allow an increase of
cap-dependent protein translation (Figure 2.1).
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Imai et al. (2008) show that overexpression of eIF4E is sufficient
to increase sensitivity to oxidative stress and dopaminergic neuronal
loss in D. melanogaster, and that co-expression of 4E-BP suppresses
this loss, suggesting that the 4E-BP/eIF4E complex is important here.
Increase in eIF4E levels, and mutations in LRRK2 that increase kinase
activity, would be expected to upregulate protein translation. That
this would lead to neuronal death may seem paradoxical. Imai et al.
(2008) hypothesise that unchecked protein translation in the context
of cell stress, being an energy intensive process, could upset the
energy balance and redox status of cells. It could also increase the
likelihood of protein misfolding events, simply by increasing the
number of proteins being produced. In contrast, inhibition of eIF4E
in C. elegans reduces protein synthesis, lowers oxidative stress and
increases lifespan (Syntichaki et al., 2007).
Here, I describe a study that seeks to ask whether the findings
described by Imai et al. (2008) can be reproduced in patient fibroblasts.
I provide preliminary data that 4E-BP is hyperphosphorylated in the
presence of disease-causing LRRK2 mutations, but not at the residues
predicted by the D. melanogaster model (Imai et al., 2008).
2.1.2 Regulation of gene expression by LRRK2
Another possible mechanism of LRRK2 pathogenesis involves an inter-
action with microRNAs (miRNAs) which are evolutionarily conserved
non-coding RNAs that regulate gene expression (Ambros, 2004).
In D. melanogaster, pathogenic LRRK2 has been shown to antag-
onise two specific miRNAs: let-7 and miR-184 (Gehrke et al., 2010).
These miRNAs normally repress the translation of E2F1 (which lies
downstream of cyclin E, a key regulator of cell cycle progression) and
DP mRNAs, and this repression is relieved when LRRK2 is mutated.
Gehrke et al. (2010) demonstrated that overproduction of E2F1 and DP
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was critical for LRRK2 pathogenesis. So, LRRK2mutations may impact
upon downstream gene expression, via E2F1-mediated transcription.
Aside from this direct modulation of gene expression, LRRK2 muta-
tions might indirectly alter gene expression via disrupting signalling
pathways.
In this chapter, I test the hypothesis that mutated LRRK2 will alter
gene expression, by comparing global gene expression in fibroblasts
cultured from PD patients carrying mutations in LRRK2 with fibrob-
lasts from healthy control subjects. This study provides data that
mutated LRRK2 does not significantly alter global gene expression
at a level detectable with the microarray platform employed. The
limitations of such a study in a non-neuronal cell type are discussed.
2.2 methods
2.2.1 Fibroblast derivation
Fibroblast cultures were isolated from PD patients with LRRK2 mu- Fibroblasts provided
by Dr Jan-Willem
Taanman, UCL
Institute of
Neurology
tations and healthy controls (summarised in Table 2.1) following ap-
proval of the study by the ethics board of the Royal Free Hospital,
London, UK and informed written consent from the individuals con-
cerned.
Skin punch biopsies (forearm) were cultured in 5 cm2 sterile Petri Biopsies performed
by Dr Daniel Healy,
Royal Free Hospital
dishes at 37ºC in 5% CO2 in 2ml DMEM supplemented with 10% Fetal
Bovine Serum (FBS), penicillin (50 U/ml) and streptomycin (50 mg/ml)
until fibroblasts were seen to migrate from the skin explants (Sly
and Grubb, 1979). Media volume was increased by 0.5 ml every 2
days. When plates were confluent, fibroblasts were lifted from dishes
by trypsinising with TrypLE (Invitrogen) and transferred to 10 cm2
dishes for culturing. Samples were designated anonymous identifiers
following collection.
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mutation lrrk2 domain n
R1441G ROC 2
Y1699C COR 1
G2019S Kinase 8
Controls – 11
Table 2.1: Patient and control fibroblast samples used.
2.2.2 Protein extraction and Western blot
Six fibroblast lines (one each of R1441G, Y1699C and G2019S and three
age matched controls) were seeded into three wells of a six-well plate
at a density of approximately 20,000 cells/cm2 (200,000 cells/well).
Media was replaced 24 hours later, and after a further 24 hours cells
were lysed (Cell Signaling Lysis buffer, Complete protease inhibitor
and Halt phosphatase inhibitor) in 100 ml buffer per well.
Protein concentration was determined with BCA Protein Assay
kit (Pierce) according to manufacturer’s instructions, and equalised
with addition of lysis buffer. Lysates were denatured via boiling with
Nupage sample buffer supplemented with DTT (dithiothreitol), and
groups of replicates were run on separate Nupage Bis-Tris 4-12%
gels in MES buffer for 70 mins at 150 V, then transferred in Tris-
glycine methanol to PVDF membrane (Millipore). Membranes were
blocked with 5% milk solution in phosphate buffered saline (PBS) for
1 hr prior to probing overnight with primary antibodies to b-actin
mouse monoclonal AC-74 (Sigma) (1:5000 dilution) in tandem with
the following 4E-BP antibodies that recognise phosphorylated motifs,
as individual experiments:
• Serine 65 (Cell Signaling #9451, rabbit polyclonal, 1:1000),
• Threonine 37/46 (Cell Signaling #9459, rabbit polyclonal, 1:1000),
• Threonine 70 (Cell Signaling #9455, rabbit polyclonal, 1:1000).
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Membranes were then probed with relevant horse radish peroxidase
(HRP) secondary antibodies and then washed three times in PBS
supplemented with 1% Tween. Chemiluminescence was determined
with the Pierce Pico Kit (Thermo Scientific). Membranes were exposed
to Kodak biomax film and developed on a Fujifilm developer as per
manufacturers instructions.
4E-BP blots were then stripped according to the following protocol:
blots were incubated with stripping buffer (2% SDS, 50 mM Tris-
HCl, 100 mM 2-mercaptoethanol, pH 6.8) for 15 to 30 mins at 50°C
with gentle shaking, then rinsed multiple times in TBS-Tween, until
2-mercaptoethanol odour had dissipated. Blots were then reprobed
for total 4E-BP independent of phosphorylation (Cell Signaling #9452,
rabbit polyclonal, 1:1000). Blots were quantitated using ImageJ (NIH).
2.2.3 RNA extraction
For collection of RNA, cultures of the 11 control and 11 LRRK2 mu-
tation cell lines described in Table 2.1 were brought to equivalent
passage by serial thawing and replating (final passage = 7). Cells were
then plated in 6 cm plates and at equal density (500,000 cells/dish).
Following 24 hrs growth, RNA was extracted using the RNeasy kit
(Qiagen) according to manufacturer’s instructions.
2.2.4 Gene expression microarray
Illumina Human HT-12 Arrays were used according to manufacturer’s Microarrays were
run by AROS AS,
Denmark
instructions, starting with 500 ng of total RNA for each sample which
was then subject to quality control using RNA integrity number (RIN),
performed prior to analysis (Schroeder et al., 2006).
Arrays were read on an Illumina Bead array reader confocal scanner.
Differential gene expression values were calculated with the Illumina
Custom algorithm within the Illumina BeadStudio software suite.
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Expression data was subjected to quantile normalisation and differ-
ential expression values calculated on sets of biological replicates. The
threshold for significance for individual genes was set at ± 1.5 fold
expression between conditions and P < 0.05. Cluster analyses were
derived using the Illumina Beadstudio software suite. Expression data
from this study are MIAME compliant and have been deposited in the
GEO database (accession number GSE25580).
2.3 results
2.3.1 Mutated LRRK2 increases 4E-BP phosphorylation
Three mutation lines (one each of R1441G, Y1699C and G2019S) and
three age matched control lines were compared. No differences in 4E-
BP phosphorylation between mutation and control lines were detected
at residues Threonine 37, 46 or 70 (Figure 2.2). However, a robust
hyperphosphorylation was seen at residue Serine 65 across all three
replicates of each of the mutation lines, when compared to wildtype
lines (Figure 2.3).
Ratio of total 4E-BP to actin was not significantly different between
lines (ANOVA and Kruskal-Wallis, P > 0.05). Ratios of Serine 65-
phosphorylated 4E-BP (Ser65-4E-BP) to total 4E-BP were not signifi-
cantly different between mutation lines (ANOVA and Kruskal-Wallis,
P > 0.05) but taken as a group, Ser65-4E-BP was significantly higher
in the mutation group compared to the control group (Student’s t-test,
P < 0.0001) (Figure 2.4).
2.3.2 Mutated LRRK2 does not alter gene expression in fibroblasts
One case (Y1699C mutation) and one control were excluded as out-
liers – given that they clustered separately to, and far from, the other
samples – which is an accepted approach to improve signal-to-noise
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Figure 2.2: Western blot of Phospho-4E-BP (Thr70 and Thr37/46). No differ-
ence in phosphorylation of 4E-BP was observed between mutation
and control fibroblast lines at these residues.
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Figure 2.3: 4E-BP is hyperphosphorylated at Ser65 in LRRK2 mutation fi-
broblasts. Representative western blot.
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(b) Quantification of Phospho-4E-BP (Ser65).
Figure 2.4: (a) ImageJ quantification shows that total 4E-BP is not signifi-
cantly different between fibroblast lines. Error bars are standard
deviations of technical replicates, n = 3. (b) ImageJ quantification
of pSer65-4E-BP corrected for total 4E-BP (left panel). Grouped
results comparing mutation lines (MT) and wildtype lines (WT)
(right panel) demonstrate significantly higher phosphorylation in
MT compared to WT (Student’s t-test, P < 0.0001).
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ratio (Kauffmann and Huber, 2010). Results from the remaining cases Assistance with gene
expression analysis
provided by Dr
Marcel van der Brug,
Genentech Inc.,
California
(n = 10) and controls (n = 10) were filtered to show probes detected
(> 0.95) and marginal detections (0.9  0.95), and then filtered on error
(standard deviation < 0.5 within cases or controls). Mann-Whitney
unpaired testing (P  0.05) was performed comparing the overall
gene expression profile between these cases and controls.
These results were filtered on fold change (> 1.5) yielding six genes
with altered expression: LOC647673, TMEM200A and IGFBP3 were
seen to increase whilst CXCL12, FGF9, and RPESP showed a decrease
in expression. However, none of these alterations survived correction
for multiple testing (Benjamini-Hochberg).
A scatter plot of cases (y-axis) versus controls (x-axis) is shown in
Figure 2.5 with 1.5-fold change from equivalent expression indicated
by green bounding lines.
2.4 discussion
The main aim of these experiments was to determine whether fi-
broblasts display an altered phenotype in the presence of mutated
LRRK2.
2.4.1 4E-BP phosphorylation study
Although preliminary, the 4E-BP phosphorylation data presented
herein are consistent with the findings from Imai et al. (2008) that 4E-
BP is phosphorylated by LRRK2. Imai et al. (2008) report that LRRK2
expression in HEK 293T cells phosphorylates 4E-BP at Thr37/46 and
Ser65, and that phosphorylation of d4E-BP was reduced in dLRRK(–/–)
flies. They suggest that 4E-BP phosphorylation in general is aug-
mented by transfecting cells with mutant LRRK2 (I2020T), and report
that some pathogenic mutations in LRRK2 (R1441G and I2020T but
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Figure 2.5: LRRK2 mutations do not significantly alter gene expression in
patient-derived fibroblasts. (a) Unsupervised cluster analysis pro-
duces a dendrogram where the mutation and control fibroblast
samples intermingle with each other. (b) Gene expression scat-
terplots compare gene expression in mutation versus control
fibroblasts. Outer bounding lines (in green) denote 1.5-fold ex-
pression change. Genes shown are those that reach significance
prior to Benjamini-Hochberg correction. LRRK2 is also shown.
No changes in gene expression survived correction for multiple
testing.
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not Y1699C) exhibit higher kinase activity at Thr37/46 than wildtype
LRRK2 under starvation (serum-free) conditions.
Here, I report that 4E-BP is hyperphosphorylated at Ser65, but
not Thr37/46 or Thr70, in patient fibroblasts with LRRK2 mutations
(G2019S, Y1699C and R1441G) compared to fibroblasts from healthy
controls. The reason for this discrepancy might be due to the difference
in cell type (fibroblasts rather than HEK 293T cells) and expression of
LRRK2 (endogenous rather than inducibly expressed).
The consequences of this difference are not clear – 4E-BP is thought
to be phosphorylated at multiple sites in a hierarchical fashion (Gin-
gras et al., 2001) so the functional impact of hyperphosphorylation at
one or other phosphosite may not necessarily be different. Imai et al.
(2008) hypothesise that phosphorylation at Thr37/46 can facilitate sub-
sequent phosphorylation at Thr70 and Ser65 in vivo by other kinases,
or possibly by LRRK2.
Nevertheless, the data presented here suggest that cultured fibrob-
lasts from patients with LRRK2 PD might have a detectable phenotype,
which warrants further investigation. As a counterpoint, and subse-
quent to the work presented here, Kumar et al. (2010) described 4E-BP
phosphorylation by LRRK2 in vitro. They reported that, whilst LRRK2
can indeed phosphorylate 4E-BP, its autophosphorylation is stronger
under conditions of molar excess of 4E-BP, and cannot be reproduced
in HEK 293T cells overexpressing LRRK2, suggesting that 4E-BP is not
a good substrate for LRRK2 – at least in this system.
The caveat with the 4E-BP study described herein is that it included
only a limited number of lines, and they were assessed without mod-
ulation of either the mTOR pathway, or of LRRK2 kinase activity.
However, one advantage over the Kumar et al. (2010) study is the use
of patient-derived cells expressing LRRK2 at endogenous levels, rather
than a cancer cell line with artifical overexpression. The next step
would be to repeat these experiments in the remaining disease and
control lines, including provocation of the mTOR pathway (through
inducing cell stress via serum withdrawal and insulin stimulation) to
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assess 4E-BP phosphorylation in a dynamic context. Also, it would be
important to establish whether 4E-BP hyperphosphorylation has the
predicted effect of increasing cap-dependent protein translation.
2.4.2 Gene expression analysis
The results of the gene expression microarray study uncovered several
genes that appeared to exhibit altered expression in the presence of
mutations versus controls. However, none of these alterations proved
to be significant when corrected for multiple testing, and all were of a
modest size (less than a two-fold change in expression). Based upon
these data, there is no significant difference in gene expression between
the grouped LRRK2 mutation fibroblasts and the control samples.
LRRK2 expression level was also found to be no different between
cases and controls. These data were incorporated into a published
study (Devine et al., 2011) along with data from two additional gene
expression microarray experiments performed by collaborators: a
comparison of occipital cortex from G2019S mutation carriers and
controls, and a comparison of HEK 293T inducible LRRK2 wildtype
and mutation cell lines. No significant alterations in gene expression
were found in these two additional experiments either, corroborating
the dataset obtained from the fibroblasts.
These findings have been substantiated by a recent comparison
of gene expression in putamen from patients with IPD, LRRK2 PD
and neurologically healthy controls (Botta-Orfila et al., 2012). Gene
expression was not found to be significantly altered in LRRK2 PD
putamen compared to controls. In contrast, differences were indeed
detected when IPD putamen was compared to control tissue – pathway
analysis found that genes involved in synaptic transmission and cell
signalling cascades were affected.
Alterations in expression of genes due to LRRK2 mutations have
been observed in two model systems. One probed expression in
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mononuclear cells isolated from G2019S mutation carriers and con-
trols, and found altered expression of genes involved in proteasomal
and mitochondrial function in the presence of mutations (Mutez et al.,
2011). The other compared gene expression in multiple tissues from
LRRK2 knockout and G2019S transgenic mice to equivalent tissue
from wildtype mice (Nikonova et al., 2012). Subtle though significant
differences in expression were found in knockout animals relative to
wildtype controls in cortex, striatum and kidney of knockout animals,
but only striatum of G2019S animals. In contrast, highly significant
differences were observed in cortex, striatum, kidney and muscle
when tissues from G2019S and knockout mice were directly compared.
Ribosomal and glycolytic pathways were upregulated in G2019S tis-
sue, whilst genes related to membrane-bound organelles, oxidative
phosphorylation, mRNA processing and endoplasmic reticulum were
downregulated in these tissues.
There are a number of factors that might help account for the
differences between these separate studies. Firstly, peripheral blood
mononuclear cells have a higher relative expression of LRRK2 com-
pared to fibroblasts (Jan-Willem Taanman, unpublished observations)
which might account for the different data obtained in this system.
Any impact of mutations upon gene expression could be dependent
on levels of LRRK2 expression raising this impact above background
variation between diverse patient genotypes. Given the relatively low
expression levels of LRRK2 in the patient fibroblasts, it is perhaps not
surprising that an alteration in overall gene expression in the mutant
lines versus the controls was not observed. It should be noted that
neither cell type has been linked to the disease process in PD, and so
a priori one would not expect a major impact of mutations upon gene
expression in either system.
A second factor to consider is the specific conditions in which the
mRNA has been isolated. The study presented herein was carried
out in fibroblasts having spent several passages in tissue culture. In
contrast, the primary cells analyzed by Mutez et al. (2011) were iso-
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lated directly from patients and not subjected to culture conditions.
The culturing of these cells may result in selective pressure against
expression of LRRK2 at a level where a pathogenically linked expres-
sion phenotype is observed. However, disease and control lines do not
show any difference in level of LRRK2 expression, suggesting that this
form of selection is unlikely. Alternatively, such a phenotype might be
silent in standard cell culture conditions, and require additional cell
stressors (e.g. oxidative stress or serum starvation) to be revealed.
Thirdly, the general background noise in the different systems must
be considered. When analysing brain tissue for example, differences
in postmortem delay, sample preparation, age of the individual and
comorbidities can all have a bearing on RNA quality and gene ex-
pression. Differences due solely to LRRK2 mutations therefore need
to be strong enough to avoid being drowned out by this noise. Put
another way, the brain tissue analysis in Devine et al. (2011) suggests
that any differences in gene expression due to LRRK2 mutations are
outweighed by differences due to sample heterogeneity.
The results of this study have specific implications for the use of
LRRK2 patient fibroblasts as a model for the disease process. Human
fibroblasts harbouring pathogenic mutations have previously been
used as a model system for neurological disorders including PD
(Hoepken et al., 2008). In the case of LRRK2 mutation fibroblasts, the
data here suggest that the focus of model development should be on
generating human neuronal systems to examine LRRK2 mutations.
In the next part of this thesis, I will describe the generation of such
a neuronal model, utilising induced pluripotent stem cell technology.
Part III
INDUCED PLURIPOTENT STEM CELLS
In this section, I describe the strategies that were employed
to reprogram human fibroblasts into induced pluripotent
stem cells. I then document the methods used to demon-
strate that cells obtained via successful reprogramming are
indeed pluripotent.
3
REPROGRAMMING METHODOLOGY
3.1 introduction
The previous chapter presented data on possible phenotypes in LRRK2
PD patient fibroblasts. However, these data are hard to reconcile: on
the one hand, preliminary data is described suggesting a possible
alteration of phosphorylation of 4E-BP, a downstream component of
the mTOR pathway, in LRRK2 fibroblasts. In contrast, gene expression
profiling suggests that the overall expression profile of the disease and
control fibroblasts is not significantly different.
Perhaps the problem here is that we are studying a neuronal disease
in a non-neuronal cell type. Ideally, we would have a human neuronal
cell model in which to study these mutations. In this chapter I will
outline the methods that I have used to generate induced pluripotent
stem cells (iPSCs) from patient fibroblasts as progress towards this
goal.
Initial testing of reprogramming methods was carried out on fibrob-
lasts from healthy subjects and fibroblasts with mutations in LRRK2.
However, whilst this part of the project was underway, fibroblasts were
obtained from members of the Iowa kindred, a large pedigree with
an early onset, rapidly progressive autosomal dominant PD caused
by triplication of the SNCA locus, encoding a-synuclein (described in
Section 1.3.1) (Singleton et al., 2003). These fibroblasts were felt to form
a more promising basis for an iPSC project, because SNCA triplication
iPSCs and their neuronal progeny should serve as a good test case
of the iPSC disease modelling paradigm. The fully penetrant, early
onset nature of SNCA triplication PD ought to maximise the chances
of observing phenotypic differences between disease and control iPSC-
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derived cells. Therefore, subsequent reprogramming attempts were
made exclusively with these fibroblasts.
The reprogramming strategies available at this time (mid 2009)
followed the same strategy as Yamanaka’s original papers (Takahashi
and Yamanaka, 2006; Takahashi et al., 2007a) i.e. delivering a set of four
genes encoding transcription factors to target cells. Most commonly,
retroviral vectors were employed to achieve this, the advantage being
that these will integrate into the target cell genome, so that when
a strong promotor is used, high levels of transgene expression will
ensue through multiple cell divisions (required for completion of
the reprogamming process (Hanna et al., 2009)). This facilitates a
high reprogramming efficiency. However, there are three potential
problems:
1. Transgenes can disrupt the target cell genome through random
integration, which may have unpredictable consequences on cell
behaviour.
2. Transgenes cannot be removed following completion of repro-
gramming, and therefore have the potential to reactivate, which
may limit the differentiation potential of the iPSCs in which they
reside.
3. Furthermore, although not the aim of this project, retention of
potentially oncogenic transgenes in reprogrammed cells would
make them unfit for therapeutic purposes.
Given all of these potential drawbacks with retroviral reprogram-
ming, much work was being conducted to develop methods of re-
programming that avoid insertion of genetic material into the target
cell genome, or would allow such inserted material to be removed
seamlessly once reprogramming had been completed.
A survey of the methods used for reprogramming human fibrob-
lasts published by November 2009 is shown in Table 3.1. Successful
reprogramming of mouse embryonic fibroblasts to iPSCs had also
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Figure 3.1: Abridged pedigree of the Iowa kindred. Arrow, proband; circles,
female; squares, male; crossed, deceased. The proband’s daughter
(ND00144) also provided fibroblasts for this study. Image derived
from the Coriell Cell Repositories website (http://ccr.coriell.
org/), where both fibroblast lines have been deposited with open
access.
been described utilising recombinant proteins (Zhou et al., 2009), but
this was still technically very challenging. Later advances in repro-
gramming methodology using mRNA (Warren et al., 2010) or miRNA
(Anokye-Danso et al., 2011) were not published at the time.
3.2 clinical details of proband
An abbreviated pedigree of the Iowa kindred is shown in Figure 3.1. Clinical details
provided by Dr
Katrina Gwinn,
National Institute of
Neurological
Disorders and Stroke
At 44 years of age, the proband was fired from a clerical job because
she was “unable to work and think fast enough”. She was treated for
depression, with some benefit in mood, but the slowness persisted.
Within a year and a half thereafter, she noted occasional activation
tremor. She had nightmares, which she acted out; she had given her
spouse injuries including a black eye during one such episode.
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At age 46, she presented to a tertiary care center with these com-
plaints; she was taking hormone replacement therapy and sertraline
at the time of presentation. She and her spouse felt that her thinking
would fluctuate, as would her motor abilities, in a matter of days or
even hours. She had spontaneous visual and auditory hallucinations.
She also noted that she felt dizzy when moving from a sitting to a
standing position.
Multiple medications were initiated including carbidopa/levodopa
with moderate benefit in bradykinesia: donepezil reportedly improved
the fluctuations in cognition, clonazepam helped the REM sleep be-
havior disorder (RBD) symptoms, and midodrine was helpful for
orthostasis. Her cognition at the time of evaluation mandated that she
be with a 24-hour caregiver to prevent accidents and wandering. Her
weight decreased from 130 to 100 lbs over the first two years of her
illness.
On examination, sitting blood pressure was 98/67 mmHg, and
pulse 81 bpm: standing blood pressure 86/60 mmHg, pulse 90 bpm.
Folstein Mini-mental status examination (MMSE) (Folstein et al., 1975)
score was 13/30, with particular difficulty on recall and sequential
tasks. She scored 14 on the Controlled Oral Word Association test
(Ruff et al., 1996) and 16 on the Beck Depression inventory (Beck and
Beck, 1972). She had marked constructional difficulties (see Figure 3.2).
She could not count backwards from 100, 20, or 12. She had marked
anosmia, scoring only 14/40 on the University of Pennsylvania Smell
Identification Test (UPSIT) (Doty et al., 1988). There was marked
hypophonia, saccadic pursuits, and moderately masked facies. She
had difficulty with rapid alternating movements. Gait was shuffling.
She took several steps backwards to prevent herself from falling on
the pull test.
Over the subsequent decade, she has become bedridden. At the
time of her clinical assessment prior to skin biopsy at age 54, she was
severely rigid, occasionally following faces with her eyes but mute to
commands and without spontaneous vocalisations or verbalisations.
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Figure 3.2: Progressive worsening of the proband’s constructional apraxia
over a three year period.
She was no longer able to eat by mouth and was tube-fed. She had
complete incontinence of bowel and bladder and required full-time
care.
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3.3.1 Fibroblast derivation
Skin biopsies were collected from the proband (age 54 at collection) Biopsies performed
by Prof Henry
Houlden, UCL
Institute of
Neurology
and her unaffected daughter (age 30 at collection). Fibroblasts were
cultured and expanded according to the methods given in Section 2.2.1.
Skin punch biopsies (forearm) were cultured in 5 cm2 sterile Petri
dishes at 37ºC in 5% CO2 in 2 ml DMEM supplemented with 10% FBS,
penicillin (50 U/ml) and streptomycin (50 mg/ml) until fibroblasts
were seen to migrate from the skin explants (Sly and Grubb, 1979).
Media volume was increased by 0.5 ml every 2 days. When plates Fibroblasts provided
by Dr Jan-Willem
Taanman, UCL
Institute of
Neurology
were confluent, fibroblasts were lifted from dishes by trypsinising with
TrypLE (Invitrogen) and transferred to 10 cm2 dishes for culturing.
Fibroblasts from the patient were designated AST (alpha-synuclein
triplication) and the daughter NAS (normal alpha-synuclein).
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3.3.2 Retroviral reprogramming – Daley method
Reprogramming of human fibroblasts was attempted following the Plasmids kindly
provided by Dr
In-Hyun Park,
Children’s Hospital
Boston
protocol as described in Park et al. (2008a). The four human reprogram-
ming factors inserted into the pMIG vector backbone are available
from Addgene:
• pMIG-hOCT4 #17225,
• pMIG-hSOX2 #17226,
• pMIG-hKLF4 #17227,
• pMIG-hcMYC #18119.
pMIG is a vector containing pMSCV (murine stem cell virus promotor)
and GFP (green fluorescent protein) separated by an IRES (internal
ribosome entry site).
The following protocol is carried out at category 2 biosafety, given
that oncogene-carrying retrovirus is produced with the ability to infect
human cells. HEK 293T cells are used as the packaging cell line.
3.3.2.1 Viral packaging
The retrovirus genome is comprised of the following three open read-
ing frames that encode for viral proteins:
• group-specific antigen (gag) encodes core and structural proteins,
• polymerase (pol) encodes reverse transcriptase, protease and
integrase,
• envelope (env) encodes retroviral coat proteins.
Viral packaging uses a cell line that is readily transfectable with sepa-
rate plasmids carrying these genes to form viral particles capable of
infecting target cells. Crucially, these plasmids lack the Y (Psi) pack-
aging signal that is required for their uptake into viral particles, and
they are therefore replication-incompetent. Instead, genes destined for
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packaging are inserted into a separate plasmid containing Y which is
also transfected into the packaging cells.
In this protocol, VSV-g, which encodes envelope proteins for the
Vesicular Stomatitis Virus (VSV), is also added to generate pseudo-
typed viral particles. These particles are capable of infecting a broader
range of target cell species. The incorporation of VSV-g also increases
stability of the viral particles and allows them to be concentrated via
ultracentrifugation.
day 0 :
• 2,000,000 HEK 293T cells are seeded in 5⇥ 10cm dishes per
retrovirus (i.e. 20 plates in total for each round of packaging)
and incubated at 37°C, 5% CO2 overnight.
• Cells are permitted to grow to approximately 70% confluency.
day 1 :
• Once HEK 293T cells are at 70% confluency, media is replaced
with fresh HEK 293T media.
• For each plate, 20 ml FuGENE 6 transfection reagent and 300 ml
media are mixed and incubated at room temperature for 5 mins.
• Add DNA to the transfection mix: 2.5 mg retroviral vector, 0.25 mg
VSV-g and 2.25 mg Gag-Pol.
• Mix and incubate at room temperature for 15 mins.
• Then add this mixture dropwise to each plate, and swirl the
media to ensure an even mix.
• Incubate at 37°C, 5% CO2 for 48 hrs.
day 3 :
• Retrovirus-containing media is collected and passed through
0.45 mm filter unit.
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• Filtered media is placed in a 38.5 ml Beckman polyallomer cen-
trifuge tube (catalogue #326823), placed in autoclaved metal cen-
trifuge buckets and balanced to within 0.01 g, then centrifuged
at 70,000 g, 4°C for 90 minutes using a Beckman XL-90 ultracen-
trifuge.
• Supernatant is then removed and the viral pellet covered in 1 ml
DMEM with gentle shaking.
• The pellet is then stored overnight at 4°C to allow it to dissolve.
day 4 :
• Pipette DMEM up and down gently with a 100 ml pipette tip
until pellet is completely dissolved.
• Carry out viral titration.
3.3.2.2 Viral titration
method 1 :
• Make a tenfold serial dilution of the viral preparation (from
undiluted to 10-6) in PBS.
• Coat a 24-well plate with poly-l-lysine to aid cell adherence.
• Add 500 ml per well, incubate for 15 mins at room temperature,
then remove liquid.
• Seed 100,000 HEK 293T cells in each well in 500 ml PBS + 0.2%
EDTA.
• Immediately add 20 ml of each viral dulution to the cells, mix
gently and the incubate at 37°C.
• GFP fluorescence should become visible 24 hours after infection
(and can be checked with a fluorescent microscope).
• Grow cells for 48 hrs. Wash cells twice with PBS to eliminate
leftover virus in the media.
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• Resuspend in PBS + 0.2% EDTA (ethylenediaminetetraacetic
acid) by pipetting up and down.
• Determine the percentage of GFP-labelled cells by FACS. Calcu-
late biological titre (BT = TU / ml, transducing units) according
to the following formula:
TU =
P⇥ N
100⇥V ⇥
1
DF
where
TU transducing units
P % GFP+ cells
N number of cells at time of transduction
V volume of dilution added to each well
DF dilution factor
method 2 :
• HEK 293T cells are plated at 75,000 cells per well of a 12-
well plate with 1 ml medium and incubated at 37°C, 5% CO2
overnight.
• To five wells, add aliquots of the vector to be titrated: use 50 ml
and 25 ml of undiluted stock, and 100 ml, 50 ml and 25 ml of a 1:50
diluted stock.
• The remaining wells are left uninfected to serve as controls.
• Incubate at 37°C, 4% CO2 for 48 hours.
• Prior to FACS, remove the medium, wash once with 2 ml PBS,
and add 500 ml of 0.25% trypsin/EDTA.
• Incubate for 5 mins at 37°C. Pipette up and down with a 1000 ml
pipette tip to break up clumps.
• Transfer to a FACS tube containing 500 ml PBS.
• Determine the percentage of GFP-positive cells.
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• Calculate the titre in TU according to the formula:
TU =
P⇥ N ⇥ 1000
V
• For accurate titre calculations, the number of GFP+ cells in two
adjacent wells must be close to the expected 1:2 ratio.
3.3.2.3 Fibroblast transduction
day 1:
• Plate out fibroblasts at 10,000 cells/well of a 6-well plate.
• Incubate at 37°C for 6 hrs to allow to sit down.
• Replace media with retroviral infection media (MEMa plus addi-
tives).
• Add virus at multiplicity of infection (MOI) of 5.
• Incubate for 24 hrs.
day 2:
• Aspirate media.
• Wash cells three times with PBS.
• Replenish media.
day 4:
• Coat dishes with 0.1% gelatin, incubate for at least 30 mins at
37°C, and seed with inactivated MEFs (2,000,000 cells per 6-well
plate).
day 5:
• Transfer infected fibroblasts onto MEFs. Add 0.2% trypsin/EDTA,
incubate for 2 to 3 mins at 37°C, inactivate with DMEM with
fetal calf serum, spin down for 2 mins at 200 g and then trans-
fer to MEF-coated dishes (1:2 split. Each well of 6-well plate
transferred to 2 wells).
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day 6:
• Change media on fibroblasts to hESC media. This first media
change is supplemented with Y27632 to promote survival of
individual cells with hESC properties.
day 8:
• Change media to fresh hESC media (KO-DMEM, 20% KSR,
2 mM l-glutamine, 1⇥ non-essential amino acids, 50 mM 2-
mercaptoethanol, 50 U/ml penicillin, 50 mg/ml streptomycin
(all from Invitrogen), and 20 ng/ml FGF2 (Peprotech)), and every
second day after that.
day 30 - 40:
• Observe for colonies and pick accordingly.
3.3.3 Transposon-based reprogramming
This method uses the piggyBAC transposon system to deliver the Plasmids kindly
provided by Dr
Keisuke Kaji,
Institute for Stem
Cell Research,
Edinburgh
transgenes to the target cells. The original publications that used this
method described generation of iPSCs from mouse embryonic fibrob-
lasts and human fetal fibroblasts, but not adult human fibroblasts (Kaji
et al., 2009; Woltjen et al., 2009). The following plasmid combinations
were trialled:
• Doxycycline-inducible expression:
– PB-TetO-MKOS-imOrange (Tetracycline operator element –
c-Myc, Klf4,Oct4, Sox2 separated by 2A peptides – mOrange
marker),
– PB-pCAG-rtTA (pCAG-driven expression of tetracycline
reverse transcriptional activator),
– pCyl43 (piggyBAC transposase).
• Constitutive expression:
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– PB-pCAG-superMKOS-imOrange (pCAG-driven expres-
sion of reprogramming factors and mOrange marker),
– pCyl43 (piggyBAC transposase).
• GFP control plasmid was included in all experiments.
IMR-90 fibroblasts (#CCL-186 from ATCC) were transfected with each
plasmid combination using Fugene HD (Roche), Lipofectamine LTX
(Invitrogen) or Nupherin (Biomol) at a range of reagent:DNA ratios
according to manufacturer’s instructions, in triplicate. Suspension
transfection was also attempted, as described by Zhang et al. (2007).
Separately, IMR-90 fibroblasts were electroporated with each plas-
mid combination using an Amaxa nucleofector (Lonza Biosciences),
according to manufacturer’s instructions.
Combinations of transfection and electroporation, and multiple
transfections on consecutive days, were also attempted.
3.3.4 Episomal reprogramming
The approach used here is as described in Yu et al. (2009). The plasmids
were obtained from Addgene:
• pEP4 E02S ET2K (OCT4, SOX2, SV40LT, KLF4 separated by
IRES) (Addgene #20927)
• pEP4 E02S CK2M EN2L (OCT4, SOX2, KLF4, c-Myc, NANOG
and LIN28 separated by IRES) (Addgene #20924)
3.3.4.1 Electroporation
day 1 :
• Plate feeder layer: irradiated MEFs in 2⇥ 6-well plates at 1,400,000
cells per plate.
• Nucleofect 1,000,000 patient fibroblasts with 10.5 mg of episomal
DNA (3.2 mg pEP4 E02S ET2K + 7.3 mg pEP4 E02S CK2M EN2L)
3.3 methods 74
using program U-23 and Human MSC Nucleofector kit (cat
#VPE-1001) with an Amaxa Nucleofector (Lonza Biosciences).
Approximately 10% survival expected.
• Plate nucleofected cells into all 12 wells of 2⇥ 6-well plates of
irradiated MEFs in MEF media.
day 2 :
• feed with hESC media supplemented with 20 ng/ml FGF2 every
second day.
day 10:
• feed with MEF-CM supplemented with 20 ng/ml FGF2 every
second day.
day 25:
• observe plates and pick colonies if present.
3.3.5 Retroviral reprogramming – Yamanaka method
The four main reprogramming factors described in the original iPSC Plasmids kindly
provided by Dr
Alison Thomson,
Roslin Institute
papers (Takahashi and Yamanaka, 2006; Takahashi et al., 2007b) were
employed. The plasmids are also available from Addgene:
• pMXs-Oct4 #13366
• pMXs-Sox2 #13367
• pMXs-cMyc #13375
• pMXs-Klf4 #13370
The protocol used here is similar to that described by Ohnuki et al.
(2009) with the major difference being that, in the published protocol,
virus is packaged with a tropism restricted to murine cells. The murine
viral receptor is first transfected into target fibroblasts so that they can
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be infected by the virus produced. This is mainly for safety reasons,
because it avoids the need to generate virus that is capable of infecting
human cells. In contrast, in the protocol detailed below, virus with
a tropism encompassing human cells is generated under category 2
level biosafety.
Human fibroblasts and mouse embryonic fibroblasts (the latter
serving as positive control) were seeded in three wells each (100,000
cells per well) of 6-well plates. These were transfected into Platinum-A
cells (Cell Biolabs #RV-102) with Lipofectamine 2000 (Invitrogen) to
package viral particles.
Target fibroblasts (100,000 cells) were transduced with virus in
the presence of 6 ng/ml polybrene (Millipore #Tr-1003-G) twice on
consecutive days, then lifted with Accutase (Invitrogen) a day later
and replated on irradiated SNL feeders (available from European
Collection of Cell Cultures, ECACC).
The day after re-plating, media was switched to hESC media sup-
plemented with 0.5 mM valproic acid (VPA) – a histone deacetylase
inhibitor shown to accelerate and improve the efficiency of reprogram-
ming (Huangfu et al., 2008). Colonies were mechanically picked after
approximately 20 days and maintained on SNL feeders in hESC media
without VPA. Established iPSC lines were maintained in hESC media
containing 10 ng/ml FGF2.
3.3.5.1 Viral packaging and fibroblast transduction
day 1 :
• Coat four 10cm dishes with 1.2 ml poly-d-lysine, incubate RTP
for 2 hrs.
• Wash three times with PBS.
• Seed 3,600,000 Plat-A cells per plate in 12 ml DMEM + FBS
without antibiotics.
day 2 :
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• One hour before transduction, change medium to Optimem, 12
ml/dish.
• Dilute 16 mg DNA with 1.5 ml Optimem.
• Dilute 60 ml Lipofectamine 2000 in 1.5 ml Optimem, incubate
RTP for 5 mins.
• Mix DNA + Lipofectamine together, incubate RTP for 20 mins.
• Add mixture to appropriate dish.
day 3 :
• Change media to DMEM + FBS, 6 ml per plate.
• Seed fibroblasts: 100,000 in each of three wells of a 6-well plate.
day 4 :
• Collect and combine 4 viral supernatants, filter 0.45 mm.
• Add to cells to be transduced (24 ml total, ~4 ml per well, 6-well
format).
• Supplement with 8 mg/ml polybrene per well.
– Two of three wells of each target lines (third being untrans-
fected control),
– One MEF positive control.
• Replenish media on transfected cells.
day 5 :
• Repeat steps ofday 4 and discard packaging cells.
• Seed feeders (irradiated SNL or MEF): 900,000 per 10 cm dish,
four dishes in total.
day 6 :
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• Lift transduced fibroblasts with Accutase (no need for ROCK
inhibitor).
• Count and seed cells on 10 cm dish of feeders (range 60,000 to
500,000 cells per dish).
• Freeze down remainder.
day 7 – 21 :
• Change media on plates to hESCmedia + 0.5mMVPA + 20 ng/ml
FGF2.
• Replace media alternate days thereafter, until colonies form.
• Then, withdraw VPA and feed daily with hESC media.
3.3.5.2 Colony picking and expansion
Once colonies are visible in the dish by eye (~ 2 to 4 mm in diameter),
they are ready to be picked. Only those colonies that have a clearly
demarcated border separating them from surrounding feeder cells
will have completed reprogramming, i.e. those with hESC colony
appearances. Colonies with an indistinct border are likely to be c-Myc
transformed or partially reprogrammed fibroblasts that will fail to
generate viable iPSC lines.
• Plate out fresh feeders in 24-well format the day prior to picking
and transferring colonies.
• Demarcate appropriate colonies to be picked under microscopic
visualisation.
• In the tissue culture hood, aspirate sufficient media from the
plate leaving a thin film of media remaining.
• Score round the edge of the colony using a P200 micropipette
tip and a Gilson pipette, holding it perpendicular to the plate, to
separate it from the surrounding feeder layer.
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• Take up a few microlitres of media into the pipette tip, then
aspirate the colony into the tip, and gently place in a dedicated
well of the the new 24-well plate.
• Repeat for each viable colony, using one well per colony.
• The day after colony transfer, withdraw VPA and feed daily with
hESC media thereafter.
• Once colonies have expanded to near confluence, or there are
signs of early differentiation, or the feeder cells are dying, the
colony should be transferred to fresh feeders, potentially to
individual wells of 6-well plates, which is the format that I have
used to maintain iPSC lines in culture.
3.4 results
3.4.1 Retroviral reprogramming – Daley method
One of the first laboratories to generate iPSCs from human cells was
that of George Daley in Boston (Park et al., 2008b). His was also the
first group to publish a full protocol on how to generate human iPSCs
(Park et al., 2008a) and we were generously given the set of plasmids
containing the four reprogramming factors that they used in their
studies. Therefore, this was the first approach that I used to try and
generate iPSCs from human fibroblasts. The method begins by using
HEK 293T cells to generate (package) retrovirus containing each of
the four reprogramming transgenes. The viral supernatants are then
spun down to concentrate the virus. These transgenes also express
GFP, which is used to titre the virus as described in Section 3.3.2.2.
The process of titration via FACS is shown in Figure 3.3.
Initial attempts used HEK 293T cells to package the virus according
to the published protocol, using separate plasmids encoding VSV-
g and gag-pol. Despite multiple and extensive rounds of packaging
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Figure 3.3: FACS titration of viral vectors. HEK 293T cells are infected with
serial dilutions of concentrated viral supernatant, viable cells
gated (shown in left panel) then analysed by FACS for expression
of GFP, and compared to uninfected control cells.
with several fresh batches of HEK 293T cells and reagents, viral titres
remained very low. At best, by pooling viral supernatant from a large
number of plates of packaging cells, virus could be produced, but at a
titre at least 10-fold lower than required.
Packaging was then switched to the Phoenix Ampho cell line (Cell
Biolabs), which already encodes VSV-g and gag-pol. Efficiency was an-
ticipated to increase, because only one plasmid (the transgene) needs
to be added to the cells in order to package viral particles bearing
the gene of interest. This did improve packaging efficiency hugely.
Nevertheless, viral packaging of these vectors gave titres of less than
1 million TU/ml at best. At multiplicity of infection (MOI) = 5, at least
500 ml of concentrated viral supernatant (of a total of 1000 ml generated
by the packaging protocol) would be needed to attempt to repro-
gram 100,000 fibroblasts. Furthermore, viral supernatant produced by
Phoenix ampho cells was more toxic to cells than supernatant taken
from HEK 293T cells, an effect noted during viral titration. Either this
was due to the direct result of a higher concentration of virus being
produced, or due to empty viral particles (i.e. transgene free) that are
continuously produced by the Phoenix Ampho cells.
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Multiple attempts were made to reprogram control human fibrob-
lasts with appropriate titres of virus, but were not successful. Infected
fibroblasts did take on a granular appearance (possibly due to the
presence of viral inclusions, implying that infection had occurred),
however hESC-like colonies did not emerge.
3.4.2 Transposon-based reprogramming
By this time, Keisuke Kaji in Edinburgh had published successful gen-
eration of iPSCs from mouse and embryonic human fibroblasts using
transposons (Kaji et al., 2009; Woltjen et al., 2009). Transposons are
DNA sequences that can move (or transpose) themselves to another
location within the genome. Transposons can be seamlessly removed
(excised) from the genome, in contrast to retrovirally-delivered trans-
genes which integrate into the host genome and remain there. This is
potentially advantageous for disease modelling with iPSCs because it
avoids continued or ectopic transgene expression which can limit the
differentiation potential of iPSCs (Hotta and Ellis, 2008). Therefore,
this was the next approach attempted.
However, despite multiple attempts with several DNA delivery
strategies, including transfection with multiple reagents, electropora-
tion, various combinations of both electroporation and transfection,
and repeated rounds of transfection, this was ultimately not success-
ful. Representative images of the most successful attempts at DNA
delivery are shown in Figure 3.4. In short, adequate DNA delivery
was not achieved.
3.4.3 Episomal reprogramming
The next approach that was explored was James Thomson’s method
using episomes (Yu et al., 2009). Episomes are the eukaryotic equiv-
alent of bacterial plasmids – generally closed DNA molecules that
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(a) GFP control.
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(b) piggyBAC plasmids.
Figure 3.4: The most efficient DNA delivery method used was a combination
of nucleofection and transfection. The fibroblasts tolerated this
approach, however there were still very few mOrange-positive
cells generated by this method. Representative images shown.
Scale bar, 100 mm.
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Figure 3.5: Immunofluorescence for Oct4 in IMR-90 fibroblast electroporated
with episomes described in Yu et al. (2009). DNA delivery was
poor at best (10 to 15% of cells, with the aim being close to 100%).
Representative images shown. Scale bar, 50 mm.
replicate autonomously in the cytoplasm. Yu et al. (2009) successfully
generated human iPSCs using a combination of two episomes carrying
OCT4, SOX2, c-Myc, KLF4, LIN28, NANOG, hTERT and SV40LT, each
gene being separated by an internal ribosome entry site (IRES). The
potential advantage with this method is that it has the potential to be
entirely integration-free. Although episomes can integrate, they can
also be spontaneously lost: subcloning of successfully reprogrammed
cell lines can identify clones where this loss has occurred or where
integration has not taken place.
Both episomes are relatively large (almost 20 kb), in part because
they both carry multiple transgenes. This perhaps explains why the
major difficulty with this approach was achieving sufficient DNA
delivery to cells. Nevertheless, a handful of colonies with phase-bright
edges did appear after one reprogramming cycle (Figure 3.6), how-
ever these failed to expand in culture. One colony (Figure 3.7) did
have hESC-like appearances, including cell morphology (high nu-
clear:cytoplasmic ratio) and reasonably distinct colony border. How-
ever, this did not expand and persist well in culture either.
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Figure 3.6: Colonies generated from episomal-based reprogramming, shown
at day 14 post electroporation (Amaxa). These have phase bright
edges, but failed to thrive in culture, and did not generate cell
lines. Representative images shown. Scale bar, 100 mm.
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Figure 3.7: Episomal transfection did generate one colony that was success-
fully expanded in culture, and initially had hESC-like appear-
ances. However, this cell line did not survive in culture for more
than a few passages. This was likely a partially reprogrammed,
or c-Myc-transformed, cell colony. Scale bar, 100 mm.
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phenotype age gender genotype line
Early onset PD 54 F SNCA triplication AST
Unaffected 30 F Daughter NAS
Unaffected 82 F Unrelated UNF
Unaffected 78 M Unrelated UNM
Table 3.2: Patient and control fibroblast lines used for reprogramming.
3.4.4 Retroviral reprogramming – Yamanaka method
In complete contrast to the methods described above, this approach
worked extremely well. Two separate rounds of reprogramming were
carried out using this method, yielding colonies with hESC-like appear-
ances from a total of four parent fibroblast lines. Fibroblasts from the
affected individual with SNCA triplication, an unaffected first-degree
relative and two further control individuals were used (summarised
in Table 3.2).
Pictures of de novo iPSC colonies are shown in Figure 3.8. These
colonies, with distinct borders and hESC morphology, are in contrast
to other colonies also generated that lack distinct borders and have a
’heaped up’ appearance (Figure 3.9). Initial characterisation focussed
on iPSC lines from the three parent fibroblast lines shown in Table 3.3,
whilst subsequent characterisation (detailed in Chapter 4) concentrated
on AST and NAS iPSC lines.
3.5 discussion
The initial methodological difficulties gave way to a robust and efficient
method of reprogramming once the originally reported method was
adopted (documented in detail in Ohnuki et al. (2009)). The fact that
this original approach is so efficient is perhaps due to the route by
which it was discovered: this reprogramming method was inevitably
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(a) Colonies derived from NAS fibroblasts.
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(b) Colonies derived from AST fibroblasts.
Figure 3.8: Phase contrast images of NAS and AST fibroblasts and de novo
iPSC colonies on SNL feeder cells at day 20 post-viral transduc-
tion. Scale bar, 100 mm.
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Fibroblasts iPSC colonies
Pax6 Tuj1 DAPIPax6 / Tuj1
Pax6 Tuj1 DAPIPax6 / Tuj1
D9 iPS
D13 Shef4
Figure 3.9: Non-iPSC colonies. Note heaped appearance and lack of distinct
(phase-bright) border. Scale bar, 100 mm.
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parent line passage colonies viable lines
AST 3 13 7
NAS 8 25 9
UNF 4 21 4
UNM 5 24 5
Table 3.3: Viable iPSC lines generated via retroviral reprogramming using
the Yamanaka vectors.
an efficient one if it were to permit iPSC generation via a screen of
hand-curated genes (Takahashi and Yamanaka, 2006).
The approach adopted by George Daley’s group (Park et al., 2008b)
differed from Yamanaka’s method in one critical respect: the promotor
used to drive transgene expression in transduced fibroblasts. They
opted for the murine stem cell virus (pMIG) promotor, rather than the
Maloney virus (pMXs) promotor used by Yamanaka. At the time (2007)
this made sense – this was before successful reprogramming of human
cells had been reported, and it was perhaps believed by Daley’s group
that this might, in part, be due to insufficient transgene expression in
emerging iPSCs. Hence, they opted for a stem cell promotor which
would yield high expression in cells with pluripotent identity, but
unfortunately expression in fibroblasts would be lower, making the
reprogramming process less efficient.
The transposon-based and episomal methods described have the
advantage that the genes used for reprogramming can be excised
once reprogramming is complete (piggyBAC transposon (Kaji et al.,
2009)) or may not integrate at all (Thomson episomes (Yu et al., 2009)).
However, major difficulties were unfortunately encountered with ap-
propriate DNA delivery. Given that patient-derived fibroblasts are a
finite and precious resource, the reprogramming method employed
had to be efficient, hence the return to a retroviral method which
worked successfully.
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The next chapter describes the demonstration of the hallmarks
of pluripotency in the iPSC lines derived from the patient and the
unaffected relative.
4
CHARACTER ISAT ION OF INDUCED PLURIPOTENT
STEM CELLS
4.1 introduction
In Chapter 3, I discussed the various approaches that were used to try
and generate iPSCs. The only robust and reproducible method found
was original approach used by Takahashi and Yamanaka (Ohnuki
et al., 2009). Multiple iPSC lines were generated from four separate
fibroblast lines. The first step was to identify iPSC clones, from each
parent fibroblast line, that could form stable lines capable of being
maintained in prolonged culture (shown in Table 3.2).
The next stage was to determine whether these putative iPSC lines
were indeed pluripotent. The original description of iPSCs used sev-
eral methods to demonstrate that the novel cell type generated had
properties similar to ESCs (Takahashi and Yamanaka, 2006). The over-
all question was how closely the novel cell type (iPSC) recapitulated
the two key features of ESC behaviour: pluripotency, and self-renewal.
4.1.1 Confirmation of pluripotency
The following characterisation was carried out by Takahashi and
Yamanaka (2006):
endogenous pluripotency gene expression: an indicator of
completion of reprogramming is that the cell’s endogenous
pluripotency genes (e.g. Oct4, Sox2, Nanog) are switched on.
This is determined via quantitative RT-PCR for these genes.
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bisulphite genomic sequencing: key pluripotency genes were
checked for promoter demethylation which is an indication of
endogenous genes being switched on.
immunocytochemistry: for surface antigens specfically expressed
in ESCs such as SSEA4 and TRA-1-81, and proteins that are
present in the pluripotent state e.g. Nanog.
gene expression microarray: transcriptional profiles of iPSCs
and ESCs are determined to see how closely they resemble each
other.
embryoid body formation: to establish that iPSCs can differen-
tiate into elements of all three germ layers in vitro.
teratoma formation: to demonstrate that iPSCs can form ele-
ments of all three germ layers in vivo.
chimaera formation: regarded as the most stringent test of pluri-
potency, that cells can contribute to the formation of an embryo,
and ultimately give rise to cells in the germ line. This test cannot
be conducted with human ESCs due to ethical reasons that are
self-explanatory.
4.1.2 Confirmation of self-renewal
telomerase activity: a defining characteristic of ES cells is the
persistence of telomerase activity, which prevents the shortening
of telomeres with cell division, hence enabling these cells to
evade senescence.
karyotype analysis: to ensure that aneuploidies and other chro-
mosomal abnormalities have not been acquired during the re-
programming process, nor during routine passage in culture.
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4.1.3 Characterisation of human iPSCs
The characterisation outlined above is necessarily thorough and com-
plete because this was the first report of a novel cell type. Subsequent
reports of the generation of human iPSCs did not include chimaera
formation for obvious reasons (Yu et al., 2007; Takahashi et al., 2007b;
Park et al., 2008b), but did recapitulate the other characterisation
methods listed above.
In this chapter, I will detail the methods used to characterise the iPSC
lines described in Chapter 3. I also discuss additional characterisation
that was carried out to confirm that the patient-derived iPSCs retained
triplication of SNCA.
4.2 methods
4.2.1 Transgene silencing and marker gene expression
RNA was obtained from separate iPSC lines using the RNeasy Plus Transgene silencing
data provided by Dr
Fatima Cavaleri,
Insitute for Stem
Cell Research,
Edinburgh
kit (Qiagen) according to manufacturer’s instructions. cDNA was
generated via Superscript III (Invitrogen), and qPCR reactions were
carried out with SYBR Green (Qiagen) on a Lightcycler 480 (Roche),
with primer pairs specific to mouse Oct4, Sox2, Klf4 and c-Myc (see
Section A.1).
Results were normalised to human TBP using the comparative C(T)
method (Schmittgen and Livak, 2008) and compared to equivalent
values determined from fibroblasts three days post-viral transduction
(positive control), Shef4 hESCs (negative control) and non-transduced
human fibroblasts (negative control). cDNA was generated from neu-
ralised iPSCs by the same method, and qPCR reactions were carried
out with the Universal Probe Library (UPL) system (Roche) and nor-
malized to GAPDH. All primers are available in Section A.1.
4.2 methods 91
4.2.2 Immunocytochemistry
Cells were fixed in 4% paraformaldehyde at room temperature, or
100% methanol at -20°C for 15 mins, then blocked and permeabilised
with blocking buffer (2% goat serum, 0.1% Triton-X in PBS) overnight
at 4°C before probing with the following primary antibodies (overnight
in blocking buffer at 4°C):
• OCT4 (Santa Cruz #5279, mouse IgG2b, 1:200),
• TRA 1-81 (Biolegend #330701, mouse IgMk, 1:600),
• SSEA4 (DSHB, mouse IgG3k, neat),
• NANOG (Abcam #ab21624, rabbit IgG, 1:1000).
Appropriate AlexaFluor-488 and AlexaFluor-596-labelled secondary
antibodies (Molecular Probes) were used, with DAPI counterstain-
ing, prior to imaging with an Olympus IX51 inverted fluorescent
microscope.
4.2.3 Embryoid body formation
iPSC colonies from separate lines were mechanically lifted intact and
seeded en bloc onto low attachment dishes (Sterilin #121V) and grown
in 20% KSR medium (hESC media without FGF2) for seven days
(feeding alternate days) after which they were plated onto tissue
culture-treated plasticware coated with 0.1% gelatin and allowed to
differentiate for a further seven days in DMEM with 10% FCS. RNA
was then extracted, and examined by qRT-PCR for expression ofMSX1,
PAX6, and AFP – marker genes representative of each of the three
germ layers (detailed in Section A.1).
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4.2.4 SNCA triplication screening
Genomic DNA was obtained from individual cell lines using the DNA
blood and tissue kit (Qiagen) according to manufacturer’s instructions,
including treatment with RNase A to remove contaminating RNA.
Dosage of SNCA was then assessed with SYBR Green qPCR on a
Rotorgene unit (Qiagen) using primers specific for exons 1 and 4
of SNCA and b2-microglobulin (B2M) and b-globin (HBB) as diploid
control genes (Ahn et al., 2008) (detailed in Section A.1).
4.2.5 SNP microarray
DNA was extracted from fibroblasts and iPSC lines using the DNeasy Microarrays were
run by AROS AS,
Denmark
Blood and Tissue Kit (Qiagen, UK) according to the manufacturer’s
instructions.
DNA was quantified spectroscopically (NanoDrop, Thermo Scien-
tific, UK) and 4 ml of 50 ng/ml gDNA and whole-genome amplified
DNA samples were marked on the Illumina Infinium Omni1-Quad
BeadChip (Illumina) according to the manufacturer’s instructions.
The BeadChips were scanned using an iScan (Illumina) with an Au-
toLoader (Illumina).
GenomeStudio v.1.8.X (Illumina) was used for analysing the data
and generating SNP calls which were created using the HumanOmni1-
Quad_v1-0_B cluster file provided by Illumina as a reference. This
data has been deposited on GEO (accession number GSE28366).
4.2.6 Gene expression microarray
Total RNA was extracted from fibroblasts and iPSC lines using the Microarrays were
run by AROS AS,
Denmark
RNeasy Plus kit (Qiagen, UK) according to the manufacturer’s instruc-
tions.
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Following the evaluation of RNA quality by capillary electrophoresis
(Agilent 2100 Bioanalyzer and RNA 6000 Nano Kit, Agilent Technolo-
gies, UK), 200 ng of total RNA was used as starting material for
the cDNA preparation. All steps starting from the first and second
strand cDNA synthesis, the In Vitro Transcription reaction to generate
cRNA and the second round of cDNA synthesis were performed us-
ing the Ambion®WT Expression Kit (Ambion, UK) according to the
manufacturer’s instructions.
Samples were then processed using the Affymetrix GeneChip Whole
Transcript Sense Target Labelling Assay and hybridised to the Affy-
metrix Exon 1.0 ST and U133 Plus 2.0 Arrays following the recom-
mended Affymetrix protocols.
Hybridised arrays were scanned on GeneChip Scanner 3000 and
visually inspected for hybridisation artefacts. The data has been de-
posited on GEO (accession number GSE28365).
4.2.7 Gene expression microarray analysis
Exon Array data generated from fibroblast lines (n = 2) and iPSC Microarray analysis
performed by Dr
Mina Ryten, UCL
Institute of
Neurology
lines (n = 4) were evaluated for uniform hybridisation intensity, ab-
normal background signals and sample outliers using Affymetrix
Expression Console (Affymetrix). All arrays were preprocessed us-
ing RMA quantile normalisation with GC background correction in
Partek’s Genomics Suite v6.5 (Partek Incorporated, USA). Only probe
sets containing a minimum of three probes, unique hybridisation and
designed against genes annotated within Entrez Gene (www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db=gene) as documented in the most re-
cent Netaffx annotation file (HuEx-1_0-st-v2 Probeset Annotations,
CSV Format, Release 31) were included in the analysis.
Gene level summary signals were generated by calculating the me-
dian expression value of all probe sets annotated to a single gene.
Principal component analysis (PCA), unsupervised hierarchical clus-
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tering, Student’s t-testing and gene expression scatterplot analyses
were performed in Partek Genomics Suite v6.5 (Partek Incorporated,
USA).
Gene set enrichment analysis (GSEA) was performed using GSEA
v2.0.6 (Broad Institute, Cambridge, MA, USA) using gene set permu-
tation and a Triplication Gene Set, which was defined as all genes
present within the triplication region (as identified on SNP array
assessment) (Subramanian et al., 2005). Following removal of batch ef-
fects, iPSC data analysed using Affymetrix U133 Plus 2.0 Arrays were
compared via Principal Components Analysis with the following data
sets, all publicly available via GEO: GSE16190, GSE19902, GSE22499,
GSE26451, GSE7179, GSE7879, GSE8590 and GSE9440.
4.3 results
4.3.1 Transgenes are silenced in a subset of iPSC lines
Given that incomplete silencing of the reprogramming transgenes
can limit the differentiation potential of iPSC lines (Hotta and Ellis,
2008) a pivotal step in screening iPSC lines for disease modelling is to
determine transgene silencing by quantitative RT-PCR for transgene
expression. A total of seven AST and nine NAS iPSC lines were estab-
lished that could be maintained and expanded in culture. Cell lines
with the strongest retroviral silencing have been shown to differentiate
more efficiently and is indicative of complete reprogramming (Hotta
and Ellis, 2008). Therefore, all lines were examined for transgene si-
lencing relative to fibroblasts three days post-viral transduction (acting
as a positive control) (Figure 4.1).
The first batch of reprogrammed cell lines had variable levels of
transgene silencing. Whilst the majority of NAS iPSC lines exhibited
good levels of transgene silencing, AST iPSC lines did not (Figure 4.1a).
Additional AST clones were generated by thawing cells that had been
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frozen at the colony picking stage. This non-clonal mixture of cells
was plated at low density yielding several dozen new colonies from
which five new clones were derived (AST9 – 14 in Figure 4.1b). When
transgene expression was examined, only one of these clones (AST13)
demonstrated efficient silencing. In order to generate additional AST
iPSC lines with efficient silencing, a second round of AST reprogram-
ming was carried out using higher titre virus by Dr Tilo Kunath,
yielding a further 13 lines (lines AST18 – 30 in Figure 4.1b).
The cell lines with the lowest observed levels of transgene expression
were chosen for further analysis. All chosen iPSC lines exhibited good
hESC colony morphology and growth characteristics, and have been
passaged more than 60 times, with more than 12 months in continual
culture.
4.3.2 Pluripotency genes are switched on in iPSC lines
Colonies from NAS and AST iPSC lines demonstrated robust ex-
pression of the pluripotency markers OCT4, SSEA4, TRA-1-81 and
NANOG (Figure 4.2). Endogenous expression of the pluripotency
genes OCT4, SOX2, NANOG and REX1 was reactivated in all iPSC
lines examined (Figure 4.3). The OCT4 and SOX2 primers do not
recognise the mouse Oct4 and Sox2 transgenes used to reprogram the
cells. No significant differences between AST and NAS iPSC lines were
observed with respect to expression of key pluripotency genes.
4.3.3 Embryoid bodies can be generated from iPSCs
Embryoid bodies derived from a sample of patient and control iPSC
lines expressed MSX1 (a marker of mesoderm), PAX6 (ectoderm) and
AFP (endoderm) (Figure 4.4). No major differences were observed in
the ability of the iPSC lines to differentiate into the three germ layers.
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(a) Reprogramming batch 1.
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(b) Reprogramming batch 2.
Figure 4.1: Quantitative RT-PCR for retroviral transgene expression of the
four reprogramming factors (Oct4, Sox2, c-Myc, Klf4). Expression
in iPSC lines was normalised to transgene expression of NAS
fibroblasts 3 days post viral transduction (NAS VT). Also shown
are negative controls: untransduced fibroblasts (NAS fibs) and
human ESCs (Shef4).
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Figure 4.2: Representative iPSC colonies derived from (a) NAS fibroblasts
and (b) AST fibroblasts stained positive for the pluripotency
markers OCT4, SSEA4, TRA-1-81 and NANOG. Scale bar, 100 mm.
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Figure 4.3: Endogenous expression of OCT4, SOX2, NANOG and REX1 in
two AST and two NAS iPSC lines, normalised to expression in
human ESCs (Shef4), found a similar expression profile in all
lines examined. Expression of these genes was absent in human
fibroblasts (not shown). Error bars represent standard deviation
of technical replicates, n = 3.
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Figure 4.4: Embryoid bodies (Day 14) from three AST and three NAS iPSC
lines were analysed for expression of MSX1 (mesoderm marker),
PAX6 (ectoderm) and AFP (endoderm) and compared to expres-
sion in the same iPSC clones. Error bars represent standard devi-
ation of technical replicates, n = 3.
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(a) Fibroblasts.
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(b) iPSCs.
Figure 4.5: Quantitative genomic PCR for SNCA exons 1 and 4 demonstrates
doubling of gene dosage in patient-derived AST iPSC lines when
compared to NAS iPSC lines. Representative data shown from
a sample of AST and NAS iPSC lines. SNCA was normalised to
b-globin (HBB) and b2-microglobulin (B2M). Error bars represent
standard deviation of technical replicates, n = 3.
4.3.4 Triplication region is retained intact
SNCA gene dosage was re-examined in the AST iPSC lines to confirm
they retained the triplication: genomic qPCR for SNCA exons 1 and
4 confirmed that AST iPSC lines had twice as many SNCA alleles as
NAS iPSC lines (Figure 4.5).
Genomic DNA samples from the two participants, the two fibroblast
lines and four iPSC lines were further analysed on genome-wide
SNP arrays. This analysis confirmed that those samples derived from
the unaffected relative were normal at Chr4q22 whilst the triplicated
region was retained intact in all samples derived from the patient
(Figure 4.6).
The triplication region (originally defined in Singleton et al. (2003))
was refined further. The size was determined to be 1.505Mb, spanning
from chr4:89,375,425 to 90,880,891 (Figure 4.7).
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(a) Unaffected relative (NAS).
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Figure 4.6: Triplication region is maintained in patient-derived fibroblasts
and iPSCs. SNP profiles of chromosome 4q22 in DNA from unaf-
fected relative blood, fibroblasts and iPSCs demonstrates that this
region is normal whilst the same region analysed in DNA from
patient blood, fibroblasts and iPSCs confirms that the triplication
region is present and is retained during reprogramming.
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Figure 4.8: Genome-wide SNP analysis of NAS9 iPSCs identified the follow-
ing chromosomal abnormalities: a small deletion at the end of
Chr4q, a duplication of part of Chr5q and an extended run of
homozygosity occupying most of Chr12q.
4.3.5 NAS9 acquired chromosomal abnormalities
SNP data was used as a virtual karyotyping method to survey the rest
of the genome for chromosomal integrity in these cell lines. Two PD
iPSC lines (AST13 and AST18) and one control iPSC line (NAS2) did
not acquire any chromosomal aberrations following reprogramming
and after more than 25 passages in culture. In contrast, one control
iPSC line, NAS9, contained a duplication of a large part of chromo-
some 5q, an extended run of homozygosity in chromosome 12q, and a
small deletion at the end of chromosome 4q (Figure 4.8).
Chromosomal abnormalities of this nature are consistent with pub-
lished reports of iPSCs where this has been specifically examined
(Mayshar et al., 2010). However, such analysis had not been reported
in the iPSC disease models published at the time (mid 2011).
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sample 1 sample 2 pi-hat
Blood DNA (AST) AST fibroblasts 0.9999
AST fibroblasts AST13 iPSCs 0.9998
AST fibroblasts AST18 iPSCs 0.9998
Blood DNA (NAS) NAS fibroblasts 0.9999
NAS fibroblasts NAS9 iPSCs 0.9797
NAS fibroblasts NAS2 iPSCs 0.9999
Blood DNA (AST) Blood DNA (NAS) 0.5
Table 4.1: Pi-hat analysis confirms origin of iPSC lines.
4.3.6 Pi-hat analysis confirms origin of iPSC lines
Pi-hat analysis (described in Dolan et al. (1999)) was used to make
comparisons between SNP data sets from each sample. This analysis
confirmed that AST and NAS iPSCs were indeed derived from the
PD patient and unaffected relative, respectively (shown in Table 4.1).
A value of 1 for Pi-hat means that the samples are identical. A value
of 0.5 means that they share 50% identity and would be expected for
first-degree relatives.
4.3.7 Gene expression profile of iPSCs
Gene expression profiling was carried out on the AST and NAS fibrob-
lasts and four iPSC lines (NAS2, NAS9, AST13 and AST18). Scatter
plots comparing gene expression of iPSCs and fibroblasts with that of
hESCs found that the expression profile of hESCs was more similar to
iPSCs than the fibroblast cell lines (Figure 4.9).
No significant differences (at false discovery rate of 0.05) in genome-
wide gene expression between human ESCs and iPSCs or NAS iPSCs
as compared to AST iPSCs could be detected.
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Figure 4.9: Scatterplots demonstrate that global gene expression of iPSCs
is more similar to hESCs than to fibroblasts and there are no
significant differences in global gene expression between AST
and NAS iPSCs.
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Figure 4.10: Multiple views of a PCA plot, following batch effect removal,
comparing iPSC gene expression to all hESC data sets on the
Affymetrix U133 Plus 2.0 platform that are publicly available.
The iPSCs intermingle within the hESC landscape in all three
dimensions, and are indistinguishable from the hESC data sets
shown.
As a stringent test to further confirm that these iPSC lines exhib-
ited a pluripotent expression profile, a comparison of global gene
expression was made with all publicly available hESC gene expression
data sets using the same platform (Affymetrix U133 Plus 2.0). A total
of 59 samples from eight separate submissions (GEO database acce-
sion numbers GSE16190, GSE19902, GSE22499, GSE26451, GSE7179,
GSE7879, GSE8590 and GSE9440) were included. The resulting PCA
plots demonstrate that the expression profiles of the iPSC lines de-
scribed are indistinguishable from established hESC lines (Figure 4.10).
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4.3.8 Summary of iPSC characterisation
A summary of characterisation of iPSC lines generated in this project
is shown in Table 4.2. For completeness, details of neuronal charac-
terisation are also included (discussed in Chapter 5). The following
lines were generated but not characterised beyond transgene silencing:
AST1, AST3, AST6, AST8 – 11, AST14, AST19, AST20, AST23 – 30,
NAS1, NAS5, NAS6, NAS7, NAS8, NAS10.
4.4 discussion
In this chapter, I describe the characterisation of sets of iPSC lines that
have been generated from two parent fibroblast lines, one of which
harbours a triplication of the SNCA locus. All the described iPSC
lines display robust transgene silencing, pluripotency gene expression
and marker profiles, and ability to generate embryoid bodies with
components of all three germ layers. The lines derived from the patient
fibroblasts have the SNCA triplication intact, determined by PCR on
genomic DNA and SNP profiling.
Teratoma formation was not assayed. Teratoma formation is re-
garded as a gold-standard of pluripotency, but is expensive to carry
out and requires use of animals, therefore strong justification would
be required to use it. In fact, this assay is not necessarily predictive
of differentiation potential in culture. Some iPSC lines are capable
of forming teratomas, but fail to differentiate into motor neurons in
standard assays (Boulting et al., 2011). Furthermore, it has been re-
ported that incompletely reprogrammed cells can also form teratomas
(Chan et al., 2009). Global transcriptional profiling is now considered
a more sensitive indicator of pluripotency and differentiation potential
(Muller et al., 2011; Bock et al., 2011). Therefore, this was the method
adopted here.
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SNP profiling identified several chromosomal abnormalities in
NAS9 iPSCs (Figure 4.8). To date, this level of chromosomal anal-
ysis is not routine in published iPSC disease models. Furthermore,
hESCs and hiPSCs have been shown to exhibit different potentials for
lineage specification, and chromosomal abnormalities do not corre-
late with these differences (Osafune et al., 2008; Boulting et al., 2011),
suggesting that the functional impact of these abnormalities may not
necessarily be detrimental to disease modelling.
In summary, bona fide iPSC lines have been generated that exhibit
the hallmarks of pluripotency. Given that the patient-derived iPSC
lines retain the triplicated region intact, this collection of lines should
serve as a useful model of PD.
In the next chapter, I discuss methods used to direct differentiation
of these cells into cultures enriched for midbrain dopaminergic neu-
rons, and describe characterisation that has been carried out on these
cultures so far.
Part IV
NEURONS
In this section, I describe the strategy used to direct the
differentiation of induced pluripotent stem cells into cul-
tures enriched for midbrain dopaminergic neurons. I then
describe the characterisation that has been carried out on
these neuronal cultures.
5
NEURALISAT ION AND NEURONAL
CHARACTER ISAT ION
5.1 introduction
Once iPSC lines have been generated and characterised in terms of
pluripotency, the next step is to direct their differentiation into cells of
interest – in this case, midbrain dopaminergic neurons.
Previous neural induction protocols have relied upon embryoid
body formation or stromal feeder co-culture, which have the draw-
backs of undefined culture conditions and low yield (Kawasaki et al.,
2000). Recent advances include the development of a feeder-free mono-
layer culture method of inducing neural differentiation under defined
conditions, via dual inhibition of SMAD signalling (Chambers et al.,
2009). This approach uses the combination of Noggin (an inhibitor of
BMP) and SB431542 (an inhibitor of Lefty/Activin/TGFb pathways) to
achieve robust neural differentiation. Here, Dorsomorphin (a further
BMP inhibitor) has been employed as a partial substitute for Noggin,
to improve efficiency and reduce costs (Yu et al., 2008).
The dual SMAD inhibition protocol has been employed to generate
floor plate tissue from human ESCs (Fasano et al., 2010). Genetic lin-
eage mapping studies in the mouse have shown that midbrain floor
plate has neurogenic potential, and is the source of ventral midbrain
dopaminergic neurons (Ono et al., 2007). Fasano et al. (2010) demon-
strated directed differentiation of human ESCs into floor plate tissue
via initial dual SMAD inhibition in conjunction with early high dose
Sonic hedgehog (SHH) signalling. They also found that suppression
of Dkk-1, a WNT inhibitor, enhanced floor plate generation at the
expense of anterior neurectoderm. Since this protocol was found to
109
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generate floor plate of the most anterior identity, the caudalising agent
WNT-1 was used to make floor plate with midbrain identity.
Hence, the approach used here was to commence neural differentia-
tion with dual SMAD inhibition for one day, followed by SHH, Wnt-1
and Dkk-1 blocking antibody treatment. Once floor plate differentia-
tion had occurred, the protocol was switched to one for the maturation
of midbrain dopaminergic neurons from neural progenitors derived
from hESCs (Perrier et al., 2004) (see Figure 5.1 for a schematic of the
entire neuralisation process).
5.2 methods
5.2.1 Dual SMAD differentiation protocol
preparation:
• iPSC cultures are incubated for 1 hr in hESC media containing
10 mM ROCK inhibitor (Y27632, Ascent)
• iPSC colonies are then dissociated using Accutase (Invitrogen)
for 20 mins, then titriated with a 5 ml stripette, to generate
single-cell suspensions.
• Suspensions are passed through a 40 mm filter (BD Biosciences)
to remove any cell clumps.
• Wash twice with hESC media.
• The suspension is then differentially plated on gelatin (1⇥ 10 cm
dish for each pair of wells from a 6-well plate) for 1 hr at 37°C in
hESC media in the presence of 10 mM Y27632, to remove feeders
and stroma.
• Non-adherent (iPS) cells are aspirated, spun down and resus-
pended in MEF-CM (R&D Systems) with 10 ng/ml FGF2 and
ROCK inhibitor.
5.2 methods 111
Da
y:
1
3
5
7
9
11
KS
R
Dk
k-
1 
Ab
12
20
No
gg
in 
+ 
SB
43
15
42
 +
 D
or
so
mo
rp
hin SH
H
BD
NF
 +
 a
sc
or
bic
 a
cid
W
nt
1
FG
F8
GD
NF
 +
 T
GF
β 
+ 
cA
M
P
Pa
ssa
ge
0
N2
M
ed
ia:
2
DMFPD
S
Fi
gu
re
5.
1:
Sc
he
m
at
ic
of
th
e
du
al
SM
A
D
in
hi
bi
tio
n
/
flo
or
pl
at
e
pr
ot
oc
ol
us
ed
to
pr
om
ot
e
di
ffe
re
nt
ia
tio
n
of
iP
SC
s
to
a
m
id
br
ai
n
do
pa
m
in
er
gi
c
ne
ur
on
al
fa
te
.D
S,
du
al
SM
A
D
in
hi
bi
tio
n;
FP
,fl
oo
r
pl
at
e
in
du
ct
io
n;
D
M
,d
op
am
in
er
gi
c
m
at
ur
at
io
n.
5.2 methods 112
• Plate on Matrigel (R&D Systems) at a density of 18,000 to 25,000
cells/cm2 (a high plating density encourages differentiation into
PAX6+ cells).
• Next day, media changed (Y27632 withdrawn) and cells allowed
to expand for three days or until nearly confluent.
day 0 :
• Once nearly confluent, switch to KSR medium (hESC medium
minus FGF2) supplemented with 50 ng/ml Noggin (Peprotech),
10 mM SB431542 (Tocris) and 2 mM Dorsomorphin (Tocris) to
make NSBDM medium.
day 1 :
• Supplement NSBDM with 200 ng/ml SHH C24II (R&D Systems)
and 50 ng/ml Wnt1 (Peprotech).
• On this day only, add Dkk-1 blocking antibody (100 ng/ml, R&D
Systems).
day 3 :
• Change media: NSBDM + SHH + Wnt1.
day 5 :
• KSR media containing these ligands is cross tapered with N2B27
media (Stem Cell Sciences) containing the same ligands over 7
days (75% KSR and 25% N2B27 first day, 50% of each third day,
and 25% KSR with 75% N2B27 fifth day).
day 7 :
• Change media: 50% KSR, 50% N2B27 supplemented with Nog-
gin, SB435432, Dorsomorphin, Shh and Wnt1.
day 9 :
• Change media: 25% KSR, 75% N2B27 supplemented with Nog-
gin, SB435432, Dorsomorphin, Shh and Wnt1.
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5.2.2 Dopaminergic neuronal differentiation protocol
The full protocol is presented schematically in Figure 5.1.
day 1 – 8 : Same as for Section 5.2.1.
day 9 :
• Change media: 25% KSR, 75% N2B27 supplemented with 20
ng/ml BDNF (Peprotech), 0.2 mM ascorbic acid (Sigma) and 100
ng/ml FGF8 (Peprotech).
day 10:
• Prepare poly-l-ornithine/laminin coated dishes by coating plates
with polyornithine (15 mg/ml) and storing at room temperature
overnight.
• Next day (day 11) wash wells three times with PBS, then coat
with laminin (1 mg/ml) in PBS and store in incubator for at least
2 hrs.
• When ready to use, aspirate wells and allow to dry for around 5
mins before adding cells.
day 11:
• Wash wells once with HBSS, then add fresh HBSS (3 ml per well)
and keep at room temperature for 60 mins (in the tissue culture
hood).
• Cells will become spheroid and not lift, but will be easily lifted
with gentle use of a cell scraper.
• Then, use a 5 ml stripette to gently break up some of the larger
clumps.
• Spin at 1300 rpm for 5
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• Resuspend in 100% N2B27 + Shh (200 ng/ml), BDNF (20 ng/ml),
ascorbic acid (0.2 mM), FGF8 (100 ng/ml).
day 12:
• Change media: 100% N2B27 supplemented with BDNF (20
ng/ml), ascorbic acid (0.2 mM), 10 ng/ml GDNF (Peprotech), 1
ng/ml TGFb3 (Peprotech) and 0.5 mM dibutyryl-cAMP (Merck).
• Thereafter, refresh media with same ligands on alternate days.
day 20 onwards:
• Analyse cells for morphology, gene expression and protein levels.
5.2.3 Immunocytochemistry
Cells were fixed in 4% paraformaldehyde at room temperature, or LMX1B antibody
kindly provided by
Prof Yu-Qiang Ding,
Tongji University
100% methanol at -20°C for 15 mins, then blocked and permeabilised
with blocking buffer (2% goat serum, 0.1% Triton-X in phosphate
buffered saline) overnight at 4°C before probing with the following
primary antibodies (also overnight in blocking buffer at 4°C):
• TUJ-1 (R&D systems #MAB1195, mouse IgG2A),
• TH (R&D systems #MAB1423 clone TH-2, mouse IgG1),
• LMX1B (Rabbit polyclonal from Dai et al. (2008), 1:2000),
• a-synuclein (BD Transduction Laboratories #610787, mouse IgG1).
Appropriate AlexaFluor-488 and AlexaFluor-596-labelled secondary
antibodies (Molecular Probes) were used at 1:1000, along with DAPI
counterstaining, prior to imaging with an Olympus IX51 inverted
fluorescent microscope or Leica DM IRE2 confocal microscope.
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5.2.4 Neuronal marker expression
RNA was obtained from individual neuralised iPSC lines using the SNCB and SNCG
expression data
provided by Dr
Masumi Nagano,
University of
Tsukuba
RNeasy Plus kit (Qiagen) according to manufacturer’s instructions.
cDNA was generated via Superscript III (Invitrogen), and qPCR reac-
tions were carried out with the Universal Probe Library (UPL) system
(Roche) and normalized to GAPDH orMAPT. All primers are available
in Section A.1.
5.2.5 Gene expression microarray analysis
Gene expression microarrays from iPSC-derived neurons were run
in tandem with RNA obtained from fibroblasts and iPSC lines, and
analysed as described in Section 4.2.7.
5.2.6 Protein analysis
Fibroblast cells, neuronal cells differentiated from AST and NAS iPSCs
and control SH-SY5Y cells were harvested in radio immunoprecip-
itation (RIPA) buffer (Cell Signaling Technologies) and protein con-
centrations estimated by BCA assay (Thermo Scientific) according to
manufacturer’s instructions.
Samples were diluted to equivalent protein concentration and then
20 mg denatured by the addition of 4⇥ sample buffer (Invitrogen)
supplemented with 2-mercaptoethanol and boiled at 100°C for 10
mins, loaded onto 12% Bis Tris Acrylamide gels (Invitrogen) and
proteins separated by SDS-PAGE.
Following transfer to cellulose or PVDF membrane, blots were
probed for:
• a-synuclein (BD Transduction Laboratories #610787),
• b-actin (Sigma-Aldrich #A1978).
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Blots were then imaged using either ECL (Pierce) and Kodak film, or
the Odyssey imaging system (LiCor Biosciences).
5.2.7 a-Synuclein secretion
To quantify a-synuclein release by neurons, 48 hr conditioned media
samples from neuralised cultures (individual wells of a 6-well plate)
were concentrated with Amicon Ultra-15 Centrifugal Filter Units (Mil-
lipore). Released a-synuclein was assessed using an a-synuclein ELISA
kit (USCN Life catalogue #E91222Hu) as per manufacturer’s instruc-
tions.
5.3 results
5.3.1 Dual SMAD inhibition generates neuronal precursors
Preliminary neuralisations were conducted using the dual SMAD
protocol in isolation. This established that the iPSC lines could be
successfully directed to differentiate into neuronal progenitors. Im-
munocytochemistry from examples are shown in Figure 5.2.
5.3.2 Dopaminergic neuralisation protocol generates TH+ neurons
Eight AST and six NAS iPSC lines were subjected to the floor plate-
dopaminergic differentiation protocol. Five AST lines and four NAS
lines produced viable neurons that could be analysed. After 20 to 31
days, differentiated iPSCs were examined for tyrosine hydroxylase (TH
– the rate limiting enzyme in the biosynthetic pathway to dopamine,
used as a marker of dopaminergic neuronal identity) and neuron-
specific class III b-tubulin (TuJ1 – used as a marker of pan-neuronal
identity) and all showed robust expression of these markers, shown in
Figure 5.3.
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Figure 5.3: Immunocytochemistry of neuralized NAS and AST iPSCs for
TuJ1 (red) and tyrosine hydroxylase (TH – green) shows robust
differentiation into dopaminergic neurons. Scale bar, 100 mm.
Blinded cell counts were performed on micrographs fluorescently
labelled for TH and TuJ1, which demonstrated that AST iPSCs yielded
37% (SD 9.5) TH-positive cells as a proportion of TuJ1-positive cells
whilst NAS iPSCs yielded 28% (SD 6.8), which is not significantly
different (P = 0.26) (Figure 5.4).
The midbrain identity of these TH-positive neurons was confirmed
by co-immunolabelling with the ventral midbrain marker LMX1B (Dai
et al., 2008) (Figure 5.5).
5.3.3 Transcriptome analysis shows enrichment for triplication genes
Gene expression profiling was carried out on the AST and NAS fi-
broblasts, four iPSC lines (AST13, AST18, NAS2, and NAS9) and eight
neuronal cultures (Day 23 and Day 31 of the 4 iPSC lines). Princi-
pal component analysis and hierarchical clustering found that the
three groups of cell samples clustered separately, with the iPSCs most
closely associated with a control hESC line, Shef4 (Figure 5.6).
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Figure 5.4: Counts of TH+ neurons, expressed as a percentage of TuJ1+ neu-
rons (n = 1955 total), found no significant difference in efficiency
of dopaminergic differentiation between AST and NAS iPSCs.
Error bars represent standard deviation of biological replicates,
n = 3.
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Figure 5.5: LMX1B (green) is expressed in the majority of TH-positive (red)
neurons (>80%). A minority of TH+ cells are negative for LMX1B
(arrowheads). Scale bar, 100 mm.
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Figure 5.6: Comparison of gene expr ssion profiles of fibroblasts, iPSCs and
neurons. (a) Principal component analysis and (b) hierarchical
clustering show that iPSCs cluster with hESCs, while fibroblasts
and neurons cluster separately. There is no clear separation be-
tween AST and NAS-derived cells at this level of analysis.
Following the creation of a triplication gene set (defined as all genes
within the triplication region, shown in Figure 4.7), Gene Set Enrich-
ment Analysis (GSEA) was used to demonstrate a highly significant
enrichment (nominal P < 0.0001) of this set within AST as compared
to NAS neurons (Figure 5.7). Although significant enrichment (nomi-
nal P < 0.05) of the Triplication Gene Set could be demonstrated in
AST versus NAS iPSCs, no significant enrichment could be detected in
AST versus NAS fibroblasts (nominal P = 0.09). Statistical significance
(nominal P value) of the enrichment score was estimated by using an
empirical gene set-based permutation test procedure, as described in
Subramanian et al. (2005).
5.3.4 Neuronal markers reveal clonal variation
To further confirm the midbrain dopaminergic identity of the cultured
neurons, expression analysis of the following neuronal markers was
performed: LMX1A, NURR1, TH and DAT (Figure 5.8). A range of
expression of these genes was observed, not linked to genotype. This
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(c) Neurons.
Figure 5.7: Gene set enrichment analysis of the triplication gene set shows
significant enrichment in AST iPSCs (nominal P < 0.05) and neu-
rons (nominal P < 0.0001) but not fibroblasts (nominal P = 0.09).
Enrichment score P-values are estimated by using an empirical
gene set-based permutation test procedure (Subramanian et al.,
2005).
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Figure 5.8: Quantitative RT–PCR analysis for midbrain dopaminergic neu-
ral markers (LMX1A, NURR1, TH and DAT) in AST and NAS
neuronal cultures. To control for efficiency of neuralisation, ex-
pression was normalised to the pan-neuronal marker MAPT.
Error bars represent standard deviation of technical replicates,
n = 3.
may reflect clonal variation, or efficiency of neuralisation which has
been previously observed in iPSCs (Hu et al., 2010).
5.3.5 Triplication region is retained in patient neurons
Genome-wide SNP analysis of AST iPSC-derived neuronal cultures
confirmed that the triplication region had remained intact during
differentiation (Figure 5.9).
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Figure 5.9: SNP analysis of AST-derived neurons confirms that the triplica-
tion region is retained intact following neuronal differentiation.
5.3.6 a-Synuclein is present in iPSC-derived neurons
a-Synuclein protein could be detected in all iPSC-derived neuronal
cultures (Figure 5.10). Considerable heterogeneity of expression of a-
synuclein was observed, which may reflect different neuronal subtypes
or different stages of neuronal maturity (Zhong et al., 2010). However,
a-synuclein was found to be expressed in all TuJ1+ cells. In contrast, it
was not detectable in fibroblasts by immunocytochemistry or western
blot (Figure 5.11).
5.3.7 a-Synuclein protein is doubled in patient neurons
To determine whether AST neurons recapitulate the elevated SNCA
expression observed in postmortem brain tissue in patients from this
kindred, and to confirm the microarray results, additional neuronal
differentiations were conducted with quantitative RT-PCR analysis
of SNCA. AST-derived neurons expressed approximately double the
quantity of SNCA mRNA as NAS-derived neurons, when controlling
for efficiency of neuralisation by normalising to the pan-neuronal
marker MAPT (Figure 5.12).
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(a) NAS iPSC-derived neurons.
α-SynDAPI
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(b) AST iPSC-derived neurons.
Figure 5.10: Expression of a-synuclein was observed in all TuJ1+ neurons
derived from (a) NAS and (b) AST iPSCs. The majority of cells
expressed low levels of a-synuclein (filled arrowheads) whereas
3 – 7% of TuJ1+ cells expressed a high level of protein (open
arrowheads). Scale bar, 100 mm upper panels, 400 mm lower
panels.
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Figure 5.11: a-Synuclein protein is not detectable in fibroblasts by either (a)
western blot (provided by Dr Patrick Lewis) or (b) immunocyto-
chemistry (using the same antibody mixtures and microscope
settings for imaging neurons). For the western blot in (a), lysate
of SH-SY5Y neuroblastoma cells transfected with an a-synuclein
expressing plasmid was used as a positive control, and b-actin
as a loading control. Scale bar, 100 mm.
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Figure 5.12: Quantitative RT-PCR data for SNCA, SNCB and SNCG shows
that expression of SNCA is significantly higher, and SNCG sig-
nificantly lower, in AST iPSC-derived neurons when efficiency
of neuralisation is controlled for, by normalising to expression
of the pan-neuronal marker MAPT. In contrast, differences in ex-
pression levels of SNCB were not observed. Error bars represent
standard deviation of technical replicates, n = 3. ***, P < 0.0005;
**, P < 0.005 (Student’s t-test, unpaired, two-tailed).
SNCA has two paralogous genes, SNCB and SNCG, which respec-
tively encode b- and g-synuclein. All have been found in neuritic
pathology in PD and dementia with Lewy bodies (DLB) (Galvin
et al., 1999). Wildtype b-synuclein inhibits a-synuclein aggregation
in vitro and limits pathology due to human a-synuclein expression
in transgenic mice, but can cause neurodegeneration when mutated
(Hashimoto et al., 2001; Fujita et al., 2010). In contrast, transgenic
overexpression of wildtype g-synuclein leads to neurodegeneration
(Ninkina et al., 2009). Overall, b-synuclein appears to be protective
whilst g-synuclein may exert its own toxicity. SNCG expression was sig-
nificantly lower in AST neurons, suggesting a possible compensatory
mechanism. No significant difference was observed in the expression
of SNCB (Figure 5.12).
To further probe the possibility of clonal variation, the level of
expression of SNCA in multiple NAS and AST iPSC lines was inves-
tigated. The iPSC lines AST13, AST18, NAS2 and NAS9 gave robust
yields of neurons on repeated trials of neuralisation. In order to con-
5.3 results 126
NA
S2
NA
S9
AS
T1
3
AS
T1
8
0
1
2
3
4
5
SN
CA
 /
 M
AP
T
NA
S2
NA
S9  
AS
T1
3
AS
T1
8
0.0
0.2
0.4
0.6
0.8
SN
CA
 /
 N
CA
M
Chr5
Chr12
duplication
homozygosity
Chr4
deletion
B 
Al
lel
e F
req
Lo
g 
R 
Ra
tio
0.0
0.5
1.0
-2
0
+2
B 
Al
lel
e F
req
Lo
g 
R 
Ra
tio
0.0
0.5
1.0
-2
0
+2
B 
Al
lel
e F
req
Lo
g 
R 
Ra
tio
0.0
0.5
1.0
-2
0
+2
Deletion
D i ation
H ozygosity
Chr4
Chr5
Chr12
Figure 5.13: Quantitative RT–PCR analysis of SNCA expression, normalized
to pan-neuronal markers (NCAM, MAPT) to directly control for
efficiency of differentiation, shows a twofold or greater increase
in SNCA expression in neurons derived from AST iPSCs. Error
bars represent standard deviation of technical replicates, n = 3.
trol for heterogeneity of neuronal differentiation, SNCA expression
was normalised to pan-neuronal markers (MAPT and NCAM). As
for the dopaminergic markers (Figure 5.8), some variation was ob-
served between lines, but a doubling (or more) of SNCA expression
was consistently found in AST-derived neurons when compared to
NAS-derived neurons (Figure 5.13).
Next, the level of a-synuclein protein expression was examined in
a pair of iPSC lines that differentiated with similar efficiency, AST18
and NAS2. A two-fold increase in a-synuclein protein expression was
observed in AST18 (Figure 5.14), which agreed with the difference in
mRNA expression.
5.3.8 a-Synuclein release is increased in patient neurons
Finally, it was asked whether AST iPSC-derived neurons might re-
lease more a-synuclein into cell culture media than NAS-derived
neurons, since this protein is known to be secreted by cells in culture
(Alvarez-Erviti et al., 2011). Conditioned media at 48 hr time points
was analysed from several AST and NAS neuronal cultures. Signifi-
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Figure 5.14: a-Synuclein protein is increased in patient-derived neurons
demonstrated by western blot (representative blot shown).
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Figure 5.15: ELISA detects significantly more a-synuclein in 48 hr condi-
tioned media from AST neuronal cultures than equivalently
conditioned media from NAS neuronal cultures. Error bars rep-
resent standard deviation of biological replicates, n = 2.
cantly more a-synuclein was found to be released into the media from
AST neurons by a sensitive ELISA method (Figure 5.15).
5.3.9 Gene set enrichment analysis of potential disease pathways
GSEA (described in Section 5.3.3) was used to assess whether the ex-
pression of sets of genes associated with specific cell pathways might
be altered in patient-derived compared with control neurons. The Ky-
oto Encyclopedia of Genes and Genomes (KEGG) Pathway database
(http://www.genome.jp/kegg/) was used as a source of hand-curated
gene sets. The following pathways were chosen based on their estab-
lished or possible link with PD pathogenesis:
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Figure 5.16: Gene set enrichment analysis provides preliminary evidence
that mTOR and proteasome gene sets are upregulated in AST
neurons.
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This analysis demonstrated a significant enrichment (nominal P<0.05)
of the mTOR and proteasome gene sets within AST as compared to
NAS neurons (Figure 5.16), whilst the other gene sets did not show
enrichment. Given that multiple tests were carried out, these results
are only provisional and need to be validated with an independent
data set.
By extending this study with more samples, additional pathways
may be highlighted which would help guide future experimental
work.
5.4 discussion
iPSC lines from the patient and unaffected relative have been suc-
cessfully differentiated into TH+ neurons with midbrain identity.
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Persistence of gene dosage doubling has been confirmed in these
neurons, and a more than two-fold higher expression of SNCA in the
patient-derived neurons has been demonstrated in a subset of lines.
Furthermore, provisional results from an analysis of transcriptome
data from iPSC-derived neuronal cultures suggest that genes asso-
ciated with the mTOR and proteasome pathway are upregulated in
cultures bearing SNCA triplication. Both of these pathways have been
implicated in PD pathogenesis. Proteasomal dysfunction is seen in
sporadic Parkinson’s disease (McNaught et al., 2003) and mTOR dys-
function has been implicated as the pathological mediator of mutations
in LRRK2 (outlined in Section 2.1.1). Taken together, these findings
suggest that this collection of cell lines has the potential to be a useful
cell model of PD.
5.4.1 Interpretation of iPSC disease models is constrained by variation
In the model presented here, each neuronally differentiated patient-
derived iPSC clone is expected to exhibit a doubling of SNCA expres-
sion. Therefore, this is a simple and stringent system for examining
the robustness of the iPSC disease-modelling paradigm. The data
presented here highlight two potential sources of variation: differences
between iPSC clones, and differences in response to neuralisation, reit-
erating existing reports of the differentiation capacity of iPSC lines (Hu
et al., 2010; Feng et al., 2010). Many genetic and epigenetic changes
occur during reprogramming (Gore et al., 2011; Hussein et al., 2011;
Lister et al., 2011), highlighting the importance of generating multiple
iPSC lines from each parent fibroblast line, so that clonal variation can
be taken into account when comparing disease and control lines.
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5.4.2 Avoiding variation due to genetic heterogeneity
Differences in genetic background between patient and control may
contribute to differences in phenotype, not specifically due to disease-
causing mutations. Fibroblasts were obtained from a patient and
a first-degree relative, to minimise this. However, the ideal system
would be a cell line with a disease-causing mutation, which is then
genetically corrected, creating cell lines that are isogenic apart from
the disease-associated locus. This has been carried out to correct the
genetic defect in Fanconi anaemia iPSCs (Raya et al., 2009). Newer
methods involving zinc finger nucleases (ZFNs) and more recently
transcription activator-like effector nucleases (TALENs) have made
this process more efficient (Hockemeyer et al., 2009, 2011) and ZFNs
have recently been used to correct A53T and A30P SNCA mutations in
iPSCs bearing these mutations (Soldner et al., 2011). These techniques
can also be used with human ESC lines, avoiding iPSC technology
altogether. However, a possible advantage of patient-derived iPSCs
is that the disease-causing mutation is present in the context of the
disease phenotype. Generating the same mutations in a different
genetic background may be an oversimplification, particularly for
diseases with a polygenic basis, but likely also for monogenic diseases
(as is the case here) where the penetrance is variable.
As an extension of this, an important additional control for this
project would be to knockout additional copies of SNCA to restore
diploidy in the patient-derived neurons, to verify that any pheno-
typic differences are due to SNCA overexpression and not due to
overexpression of any other gene in the triplicated region. Gene tar-
geting employing ZFNs or TALENs would be a valid approach. An
alternative strategy would be to employ RNA interference to knock-
down SNCA expression. This has been used successfully to deplete
a-synuclein in cell cultures (Fountaine et al., 2008).
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5.4.3 Minimising variation due to cell type heterogeneity
It is important to note that current ESC and iPSC differentiation pro-
tocols generate heterogenous populations of cells, albeit populations
enriched for cell types of interest. Narrowing the cellular type derived
from stem cells is a challenge to using these cells. Potential solutions
to this include employing fluorescence activated cell sorting (FACS)
strategies to enrich for cells of interest, with or without cell-type
specific lineage reporters. Currently, no cell surface markers of hu-
man dopaminergic neurons are available, though antibodies directed
against Corin have been used successfully in mouse (Ono et al., 2007).
An alternative would be to examine the differentiated population on a
single cell basis, either via blinded single cell PCR, which would be
extremely laborious, or using laser-capture microdissection.
Part V
CONCLUS ION
6
CONCLUS IONS AND FUTURE DIRECT IONS
6.1 a brief summary
This thesis has utilised iPSC technology to develop a novel human cell
model of PD. Given that the iPSC field was new at the time of project
development, a degree of risk was involved. Therefore, studies were
also conducted on patient-derived skin fibroblasts as a safer parallel
project. These yielded mixed results, the overall impression being that
fibroblasts are not the optimal cell type in which to study a neuronal
disease. Generation of a cell model with closer affinity to the cells
that are specifically vulnerable in PD may be required to see the toxic
effects of mutant LRRK2 – corroborating the iPSC approach to model
disease.
Generation of iPSCs from adult human fibroblasts proved to be tech-
nically challenging. Several different approaches were tried in earnest
before a method was adopted that could successfully reprogram adult
human fibroblasts with sufficient efficiency to use with patient sam-
ples. Use of retrovirus bearing the four transcription factors Oct4, Sox2,
c-Myc, and Klf4, as originally described by Takahashi et al. (2007b),
proved to be a reliable and efficient reprogramming strategy.
Thus far, all iPSC disease models have employed retroviral-based
reprogramming factors, which integrate into the genome of target
cells. These integration sites will be different for separate iPSC clones.
Although unlikely, given the size of the entire genome relative to that
portion that is expressed or important for regulation of expression,
these different integrations may have a bearing on cell behaviour.
This can be circumvented by using an integration-free method of
reprogramming (Okita et al., 2008; Stadtfeld et al., 2008; Zhou et al.,
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2009; Gonzalez et al., 2009; Yu et al., 2009; Fusaki et al., 2009; Warren
et al., 2010; Okita et al., 2011), or one in which the reprogramming
factors can be seamlessly removed (Kaji et al., 2009; Woltjen et al.,
2009). However, patient-derived cells are a finite resource, and these
techniques currently lack the reprogramming efficiency needed to
generate iPSC lines from a limited number of cells, although recent
improvements in episomal reprogramming techniques are showing
promise (Okita et al., 2011).
6.2 recapitulating a disease of aging
Returning to the original hypothesis of the project, is the iPSC paradigm
appropriate for studying PD? The long latency of PD, being more com-
mon in old age, is challenging to mimic in a cell culture system (Saha
and Jaenisch, 2009). Also, any contribution made by epigenetic factors
to the disease process would be erased during the iPSC reprogram-
ming process. This is why a fully penetrant, early onset and rapidly
progressive familial form of PD was chosen to offset these two prob-
lems as far as possible. The data presented herein supports the thesis
that a human neuronal model can replicate the genetic insult that re-
sults in disease in patients with SNCA triplication, but whether these
cell lines recapitulate PD pathogenesis in vitro remains uncertain.
Soldner et al. 2009 described the first iPSC model of PD, using
fibroblasts from patients with sporadic disease as a starting point, but
a phenotype has not been documented as yet. More recently, Nguyen
et al. (2011) have shown that neurons derived from iPSCs bearing
mutations in LRRK2 are more susceptible to oxidative stress. Sánchez-
Danés et al. (2012) have described a large set of LRRK2 iPSC lines
(derived from seven patients): neurons derived from these cells accu-
mulate autophagic vacuoles and exhibit reduced neurite outgrowth. A
very recently published report of iPSCs bearing triplication of SNCA
(derived from fibroblasts from a different donor than reported here,
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but from the same kindred) has shown that neurons derived from
these cells appear to be more sensitive to oxidative stress (Byers et al.,
2011). An iPSC model of PINK1-associated PD has also been reported
(Seibler et al., 2011). Dopaminergic neurons derived from these cells
exhibited impaired recruitent of lentivirally expressed parkin to mito-
chondria, reiterating previous reports of this phenomenon in knock-
down systems and non-neuronal cell models (Narendra et al., 2010;
Rakovic et al., 2010; Vives-Bauza et al., 2010). Although these reports
do not necessarily provide novel insight into disease mechanisms, they
certainly support the view that cells in culture can go some way to
recapitulating disease processes seen in PD.
Indeed, it is important to emphasise that such models can be seen as
a system in which the early pathogenic changes that lead to disease can
be studied, rather than a model in which the fully fledged end stage
pathology of PD can be observed. This is potentially advantageous
for two reasons. First, observing these earliest responses might afford
greatest hope for deriving a treatment that can stop the disease before
it progresses. Second, pathological changes occurring at a late stage in
the disease may in fact be protective rather than toxic (Cookson and
van der Brug, 2008).
The model reported here opens the door to more complex cellu-
lar PD model systems, for example co-culture of neuronal and glial
populations. It is likely that different cell types found in the brain
contribute to the disease process in PD, paralleling the situation in
amyotrophic lateral sclerosis (Wernig et al., 2008; Ilieva et al., 2009).
Taking advantage of progress in stem cell technology, both mutant and
wildtype glial and neuronal cells can be co-cultured to generate a more
representative cellular model for PD (Di Giorgio et al., 2007). These
cells might also prove useful in investigating cell-to-cell propagation
of pathology, being pre-primed to develop disease (Brundin et al.,
2008).
iPSCs carrying the SNCA triplication may also be of value in study-
ing the related synucleinopathies in vitro – the pathology exhibited by
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the Iowa kindred includes cases where glial deposition of a-synuclein,
reminiscent of the glial cytoplasmic inclusions found in MSA, is de-
scribed (Gwinn-Hardy et al., 2000). The differentiation of these iPSC
lines towards an oligodendroglial fate may shed light on the cellular
processes operating in this disorder (Wenning et al., 2008). In addi-
tion, differentiation towards cortical neurons (recently described by
Shi et al. (2012)) might provide insight into a-synuclein pathogenesis
in DLB, where pathology is largely cortical. Comparisons between
cortical neurons and dopaminergic neurons would also be of interest
in examining why different neuronal subtypes appear to differ in their
susceptibility to the disease mechanisms operating in PD.
6.3 potential future directions
6.3.1 Synaptic transmission
In this thesis, cells are described that exhibit neuronal morphology,
and also express markers of midbrain dopaminergic identity. An im-
portant next step is to establish that these cells behave like neurons –
having the capacity to fire action potentials, and release neurotrans-
mitters, phasically and evoked. This further characterisation would
be desirable when using iPSC-derived neuronal cells to model any
disease, but is particularly warranted in the context of PD: presynaptic
accumulation of a-synuclein is known to occur in neurodegeneration
(Kramer and Schulz-Schaeffer, 2007) and overexpression of a-synuclein
impairs neurotransmitter release (Nemani et al., 2010). Furthermore,
a-synuclein facilitates the formation of complexes of SNARE (soluble
NSF attachment protein receptor) proteins (Burré et al., 2010). SNARE
proteins mediate vesicle fusion to allow exocytosis of transport vesi-
cles, and play a pivotal role in permitting the precisely timed and
targetted release of neurotransmitters at the synapse (Südhof and
Rothman, 2009).
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Taken together, these studies suggest that PD – in particular when
due to a-synuclein overabundance – may begin at the synapse, and
spread from there. Indeed, deletion of Munc18-1, which prevents
synaptic transmission during development, leads to widespread neu-
rodegeneration in mouse, whilst synaptic formation proceeds as nor-
mal, implying that transmission is a requirement of maintainenance
of neuronal integrity, but not development (Verhage et al., 2000).
Therefore, an important avenue to explore is whether midbrain
dopaminergic neurons bearing triplication of SNCA have impaired
release of dopamine in response to firing action potentials with con-
sequent influx of calcium, hence recapitulating the mouse model.
The next step would be to study the mechanistic basis for such a
disturbance, if it were present.
6.3.2 Mitochondrial physiology
The importance of mitochondria in maintaining the health of midbrain
dopaminergic neurons was highlighted by the accidental exposure
of a group of Californian drug users to the neurotoxin MPTP in the
early 1980s (Langston et al., 1983). This caused an acute, irreversible
Parkinsonian syndrome via the MPTP metabolite MPP+, which in-
hibits complex I of the mitochondrial electron transport chain, causing
increased free radical production and increased intracellular calcium
via decreased ATP. Reduced complex I activity has also been found in
sporadic PD brain at postmortem (Schapira et al., 1989). A causal link
has been provided by chronic systemic administration of the complex I
inhibitor rotenone to rats, which subsequently develop a Parkinsonian
syndrome with a-synuclein inclusions (Betarbet et al., 2000).
The link between mitochondrial dysfunction and PD has been re-
inforced by the analysis of PD caused by mutations in parkin Kitada
et al. 1998, PINK1 (Valente et al., 2004) and DJ1 (Bonifati et al., 2003).
PINK1 encodes a serine-threonine kinase with an amino-terminal mi-
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tochondrial import sequence. It seems to have a role in maintaining
mitochondrial integrity in the face of cellular stressors (Pridgeon et al.,
2007). PINK1 and parkin function in a common pathway to regulate
mitochondrial dynamics: parkin overexpression rescues mitochon-
drial abnormalities seen in Pink1-knockout flies and PINK1 silenced
mammalian cells (Park et al., 2006; Clark et al., 2006; Exner et al.,
2007), suggesting that it operates downstream of PINK1. At normal
expression levels, PINK1 is required for the recruitment of parkin to
damaged mitochondria for their clearance via mitophagy (Narendra
et al., 2008). Furthermore, mice and fly brains are rendered sensitive
to oxidative stress when DJ1 is knocked down by small interfering
RNA (Kim et al., 2005) and DJ1-deficient cells display an aberrant
mitochondrial phenotype that can be rescued with the expression
of parkin or PINK1, or by applying ROS scavengers (Irrcher et al.,
2010). Overall, the possibility of finding mitochondrial pathology in
the patient-derived neurons described herein should be a fruitful area
to examine.
6.4 concluding remarks
This thesis is a demonstration of the feasibility of generating iPSCs
and midbrain dopaminergic neurons from a patient with a fully pene-
trant form of familial PD. It also highlights that, in its current form,
the inherent variation in iPSC clones, neuronal differentiations and
expression of disease-related genes will make the interpretation of
these models challenging.
Part VI
APPENDIX
A
APPENDIX
a.1 pcr primers
gene primer sequence 5´ - 3´ sybr or upl no.
SNCA ex1 AAAGGCCAAGGAGGGAGTT
ATCCTAACCCATCACTCATGAAC
SYBR
SNCA ex4 CCTGTGGATCCTGACAATGA
TGCAAGTTGTCCACGTAATGA
SYBR
HBB TTGGACCCAGAGGTTCTTTG
GAGCCAGGCCATCACTAAAG
SYBR
B2M CTCACGTCATCCAGCAGAGA
AGTGGGGTGAATTCAGTGT
SYBR
mOct4 GTTGGAGAAGGTGGAACCAA
CTCCTTCTGCAGGGCTTTC
SYBR
mSox2 ACAGCTACGCGCACATGA
GGTAGCCCAGCTGCTCCT
SYBR
mc-Myc CCTAGTGCTGCATGAGGAGA
TCTTCCTCATCTTCTTGCTCTTC
SYBR
mKlf4 CGGGAAGGGAGAAGACACT
GAGTTCCTCACGCCAACG
SYBR
TBP GCTGGCCCATAGTGATCTTT
CTTCACACGCCAAGAAACAGT
SYBR
OCT4 TGCCGTGAAACTGGAGAAG
GCTTGGCAAATTGTTCGAGT
#78
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gene primer sequence 5´ - 3´ sybr or upl no.
SOX2 TGCTGCCTCTTTAAGACTAGGAC
CCTGGGGCTCAAACTTCTCT
#35
NANOG TCTCCAACATCCTGAACCTCA
TTGCTATTCTTCGGCCAGTT
#87
REX1 GGCCTTCACTCTAGTAGTGCTCA
CTCCAGGCAGTAGTGATCTGAGT
#62
GAPDH GCTAGGGACGGCCTGAAG
GCCCAATACGACCAAATCC
#60
NURR1 ATTTCCTCGAAAACGCCTGT
CATACTGCGCCTGAACACAA
#41
LMX1A AGAGCTCGCCTACCAGGTC
GAAGGAGGCCGAGGTGTC
#25
MAPT ACCACAGCCACCTTCTCCT
CAGCCATCCTGGTTCAAAGT
#55
NCAM GCGTTGGAGAGTCCAAATTC
GGGAGAACCAGGAGATGTCTTT
#51
SNCA GAGGGAGTGGTGCATGGT
TGCTGTCACACCCGTCAC
#68
SNCB GCGGAGAAAACCAAGCAG
ACACCTTCTCGGGTCTTGC
#70
SNCG CGGTGGAAAAGACCAAGC
CTGAGGTCACGCTCTGTACAAC
#38
DAT CCAGCTACAACAAGTTCACCAA
AGAAGCTCGTCAGGGAGTTG
#10
TH GTAAGCAGAACGGGGAGGT
TCTCAGGCTCCTCAGACAGG
#56
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a.2 antibodies
• Phospho 4E-BP (Serine 65) (Cell Signaling #9451, rabbit poly-
clonal, 1:1000)
• Phospho 4E-BP (Threonine 37/46) (Cell Signaling #9459, rabbit
polyclonal, 1:1000)
• Phospho 4E-BP (Threonine 70) (Cell Signaling #9455, rabbit poly-
clonal, 1:1000)
• b-actin (Sigma clone AC-74 #A2228, mouse IgG2a, 1:5000)
• total 4E-BP (Cell Signaling #9452, rabbit polyclonal, 1:1000)
• OCT4 (Santa Cruz #5279, mouse IgG2b, 1:200)
• TRA 1-81 (Biolegend #330701, mouse IgMk, 1:600)
• SSEA4 (DSHB, mouse IgG3k, neat)
• NANOG (Abcam #ab21624, rabbit IgG, 1:1000)
• TUJ-1 (R&D systems #MAB1195, mouse IgG2A)
• TH (R&D systems #MAB1423 clone TH-2, mouse IgG1)
• LMX1B (Rabbit polyclonal from Dai et al. (2008), 1:2000)
• a-synuclein (BD Transduction Laboratories #610787, mouse IgG1)
• AlexaFluor-488 and AlexaFluor-596-labelled secondary antibod-
ies (Molecular Probes)
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